Peter J Barnes

List of Publications by Citations

871 papers	91,171 citations	147 h-index	274 g-index
956 ext. papers	100,897 ext. citations	8.8 avg, IF	8.77 L-index

#	Paper	IF	Citations
871	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 532-55	10.2	5242
870	Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *New England Journal of Medicine*, **1997**, 336, 1066-71	59.2	4072
869	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 347-65	10.2	3654
868	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 557-582	10.2	1682
867	Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet, The*, **2000**, 356, 2144-8	40	1473
866	Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. *New England Journal of Medicine*, **1997**, 337, 1405-11	59.2	1272
865	Increased nitric oxide in exhaled air of asthmatic patients. *Lancet, The*, **1994**, 343, 133-5	40	1227
864	Systemic manifestations and comorbidities of COPD. *European Respiratory Journal*, **2009**, 33, 1165-85	13.6	1041
863	Chronic obstructive pulmonary disease. *New England Journal of Medicine*, **2000**, 343, 269-80	59.2	1036
862	Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *European Respiratory Journal*, **2003**, 22, 672-88	13.6	1015
861	Immunology of asthma and chronic obstructive pulmonary disease. *Nature Reviews Immunology*, **2008**, 8, 183-92	36.5	981
860	Chronic obstructive pulmonary disease in non-smokers. *Lancet, The*, **2009**, 374, 733-43	40	832
859	Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *New England Journal of Medicine*, **2005**, 352, 1967-76	59.2	769
858	Glucocorticoid resistance in inflammatory diseases. *Lancet, The*, **2009**, 373, 1905-17	40	726
857	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *European Respiratory Journal*, **2019**, 53,	13.6	722
856	The cytokine network in asthma and chronic obstructive pulmonary disease. *Journal of Clinical Investigation*, **2008**, 118, 3546-56	15.9	652
855	Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. *Molecular and Cellular Biology*, **2000**, 20, 6891-903	4.8	614

854	Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 16-27	11.5	612
853	Anti-inflammatory actions of steroids: molecular mechanisms. *Trends in Pharmacological Sciences*, **1993**, 14, 436-41	13.2	600
852	Isoprostanes: markers and mediators of oxidative stress. *FASEB Journal*, **2004**, 18, 1791-800	0.9	553
851	Mediators of chronic obstructive pulmonary disease. *Pharmacological Reviews*, **2004**, 56, 515-48	22.5	544
850	Inhaled glucocorticoids for asthma. *New England Journal of Medicine*, **1995**, 332, 868-75	59.2	530
849	Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. *Journal of Experimental Medicine*, **2006**, 203, 7-13	16.6	506
848	How corticosteroids control inflammation: Quintiles Prize Lecture 2005. *British Journal of Pharmacology*, **2006**, 148, 245-54	8.6	490
847	Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. *European Respiratory Journal*, **1997**, 10, 1683-93	13.6	452
846	Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. *Journal of Allergy and Clinical Immunology*, **2013**, 131, 636-45	11.5	451
845	Histone acetylation and deacetylation: importance in inflammatory lung diseases. *European Respiratory Journal*, **2005**, 25, 552-63	13.6	449
844	Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. *Respiratory Medicine*, **2008**, 102, 593-604	4.6	421
843	Nitric oxide and asthmatic inflammation. *Trends in Immunology*, **1995**, 16, 128-30		416
842	COPD as a disease of accelerated lung aging. *Chest*, **2009**, 135, 173-180	5.3	415
841	Oxidative stress in COPD. *Chest*, **2013**, 144, 266-273	5.3	414
840	Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 1497-504	10.2	409
839	Reactive oxygen species and airway inflammation. *Free Radical Biology and Medicine*, **1990**, 9, 235-43	7.8	407
838	New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. *Journal of Allergy and Clinical Immunology*, **1989**, 83, 1013-26	11.5	405
837	A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 8921-6	11.5	400

836	A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 549-58	10.2	393
835	Neuropeptides in the respiratory tract. Part I. *The American Review of Respiratory Disease*, **1991**, 144, 1187-98		375
834	A new approach to the treatment of asthma. *New England Journal of Medicine*, **1989**, 321, 1517-27	59.2	375
833	Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. *Journal of Experimental Medicine*, **2004**, 200, 689-95	16.6	373
832	Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. *New England Journal of Medicine*, **1980**, 303, 263-7	59.2	371
831	Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. *FASEB Journal*, **1998**, 12, 929-937	0.9	364
830	Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. *The American Review of Respiratory Disease*, **1993**, 148, S1-26		364
829	Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. *Biochemical and Biophysical Research Communications*, **1997**, 237, 28-32	3.4	354
828	Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. *European Respiratory Journal*, **2002**, 19, 182-91	13.6	352
827	Sex and gender: modifiers of health, disease, and medicine. *Lancet, The*, **2020**, 396, 565-582	40	347
826	Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. *American Journal of Respiratory Cell and Molecular Biology*, **2002**, 26, 602-9	5.7	342
825	p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. *Journal of Allergy and Clinical Immunology*, **2002**, 109, 649-57	11.5	340
824	Glucocorticosteroids: current and future directions. *British Journal of Pharmacology*, **2011**, 163, 29-43	8.6	337
823	Theophylline: new perspectives for an old drug. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 813-8	10.2	337
822	Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. *European Respiratory Journal*, **2002**, 20, 556-63	13.6	337
821	Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet, The*, **2000**, 356, 2149-53	40	335
820	Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. *New England Journal of Medicine*, **1992**, 327, 1204-8	59.2	320
819	Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. *Lancet, The*, **2004**, 363, 731-3	40	316

818	Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. *Biochemical and Biophysical Research Communications*, **2004**, 315, 240-5	3.4	308
817	A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. *New England Journal of Medicine*, **1997**, 337, 1412-8	59.2	298
816	Nuclear factor-kappa B. *International Journal of Biochemistry and Cell Biology*, **1997**, 29, 867-70	5.6	297
815	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. *European Respiratory Journal*, **2017**, 49,	13.6	295
814	Corticosteroid effects on cell signalling. *European Respiratory Journal*, **2006**, 27, 413-26	13.6	290
813	Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. *European Journal of Pharmacology*, **1992**, 210, 221-2	5.3	285
812	Cellular and molecular mechanisms of chronic obstructive pulmonary disease. *Clinics in Chest Medicine*, **2014**, 35, 71-86	5.3	284
811	Exhaled nitric oxide in pulmonary diseases: a comprehensive review. *Chest*, **2010**, 138, 682-92	5.3	281
810	New anti-inflammatory targets for chronic obstructive pulmonary disease. *Nature Reviews Drug Discovery*, **2013**, 12, 543-59	64.1	280
809	The costs of asthma. *European Respiratory Journal*, **1996**, 9, 636-42	13.6	278
808	Chronic obstructive pulmonary disease. *Nature Reviews Disease Primers*, **2015**, 1, 15076	51.1	270
807	Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 897-904	10.2	269
806	Theophylline. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 901-6	10.2	268
805	Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. *New England Journal of Medicine*, **2018**, 378, 1865-1876	59.2	265
804	Expression and activity of histone deacetylases in human asthmatic airways. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 392-6	10.2	257
803	Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2004**, 287, L774-83	5.8	249
802	Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 24-31	10.2	248
801	The cytokine network in chronic obstructive pulmonary disease. *American Journal of Respiratory Cell and Molecular Biology*, **2009**, 41, 631-8	5.7	247

800	Lipopolysaccharide treatment in vivo induces widespread tissue expression of inducible nitric oxide synthase mRNA. *Biochemical and Biophysical Research Communications*, **1993**, 196, 1208-13	3.4	243
799	Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. *Journal of Allergy and Clinical Immunology*, **2015**, 136, 769-80	11.5	241
798	Measurement of exhaled nitric oxide in children, 2001. *European Respiratory Journal*, **2002**, 20, 223-37	13.6	241
797	Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. *British Journal of Pharmacology*, **1994**, 113, 1008-14	8.6	240
796	Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. *European Respiratory Journal*, **2003**, 21, 433-8	13.6	239
795	The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 753-62	10.2	235
794	Alveolar macrophages as orchestrators of COPD. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2004**, 1, 59-70	2	235
793	Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. *Nature Medicine*, **1996**, 2, 814-7	50.5	234
792	Oxidative stress induces NF kappa B DNA binding and inducible NOS mRNA in human epithelial cells. *Biochemical and Biophysical Research Communications*, **1994**, 199, 1518-24	3.4	232
791	Cellular and molecular mechanisms of asthma and COPD. *Clinical Science*, **2017**, 131, 1541-1558	6.5	228
790	How do corticosteroids work in asthma?. *Annals of Internal Medicine*, **2003**, 139, 359-70	8	225
789	Role of HDAC2 in the pathophysiology of COPD. *Annual Review of Physiology*, **2009**, 71, 451-64	23.1	224
788	Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 134-41	10.2	224
787	As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. *New England Journal of Medicine*, **2018**, 378, 1877-1887	59.2	223
786	Pathophysiology of allergic inflammation. *Immunological Reviews*, **2011**, 242, 31-50	11.3	221
785	Nitric oxide and airway disease. *Annals of Medicine*, **1995**, 27, 389-93	1.5	220
784	Mechanisms and resistance in glucocorticoid control of inflammation. *Journal of Steroid Biochemistry and Molecular Biology*, **2010**, 120, 76-85	5.1	219
783	The effect of airway epithelium on smooth muscle contractility in bovine trachea. *British Journal of Pharmacology*, **1985**, 86, 685-91	8.6	219

782	Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. *Chest*, **2002**, 122, 1162-7	5.3	217
781	Biomarkers of some pulmonary diseases in exhaled breath. *Biomarkers*, **2002**, 7, 1-32	2.6	217
780	Transcription factors and asthma. *European Respiratory Journal*, **1998**, 12, 221-34	13.6	217
779	Neurogenic inflammation in the airways. *Respiration Physiology*, **2001**, 125, 145-54		214
778	New concepts in chronic obstructive pulmonary disease. *Annual Review of Medicine*, **2003**, 54, 113-29	17.4	213
777	Pulmonary biomarkers in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 6-14	10.2	212
776	Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 141-7	10.2	211
775	Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. *The American Review of Respiratory Disease*, **1990**, 141, 1559-68		208
774	Mechanisms in COPD: differences from asthma. *Chest*, **2000**, 117, 10S-4S	5.3	205
773	Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. *Lancet, The*, **1987**, 1, 248-51	40	204
772	Importance of inhaler devices in the management of airway disease. *Respiratory Medicine*, **2008**, 102, 10-9	4.6	203
771	Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 542-8	10.2	197
770	Neuropeptides in the respiratory tract. Part II. *The American Review of Respiratory Disease*, **1991**, 144, 1391-9		196
769	Corticosteroids: the drugs to beat. *European Journal of Pharmacology*, **2006**, 533, 2-14	5.3	194
768	Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 1117-24	10.2	191
767	Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 704-12	10.2	191
766	Difficult asthma. *European Respiratory Journal*, **1998**, 12, 1209-18	13.6	191
765	Accelerated ageing of the lung in COPD: new concepts. *Thorax*, **2015**, 70, 482-9	7.3	187

764	Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. *Chest*, **2003**, 123, 1240-7	5.3	185
763	Exhaled leukotrienes and prostaglandins in asthma. *Journal of Allergy and Clinical Immunology*, **2002**, 109, 615-20	11.5	185
762	A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. *FASEB Journal*, **2009**, 23, 2810-9	0.9	184
761	Molecular mechanisms of corticosteroid resistance. *Chest*, **2008**, 134, 394-401	5.3	184
760	Exhaled biomarkers. *Chest*, **2006**, 130, 1541-6	5.3	184
759	NF-kappa B: a pivotal role in asthma and a new target for therapy. *Trends in Pharmacological Sciences*, **1997**, 18, 46-50	13.2	179
758	Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. *Nature Reviews Immunology*, **2018**, 18, 454-466	36.5	177
757	Muscarinic receptor subtypes in airways. *Life Sciences*, **1993**, 52, 521-7	6.8	177
756	Theophylline in the management of asthma: time for reappraisal?. *European Respiratory Journal*, **1994**, 7, 579-91	13.6	176
755	Chronic obstructive pulmonary disease and lung cancer: new molecular insights. *Respiration*, **2011**, 81, 265-84	3.7	175
754	Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. *European Respiratory Journal*, **1996**, 9, 196-201	13.6	175
753	Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2002**, 283, L867-73	5.8	173
752	Therapeutic strategies for allergic diseases. *Nature*, **1999**, 402, B31-8	50.4	173
751	Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. *British Journal of Pharmacology*, **1996**, 118, 1945-58	8.6	173
750	Increased pulmonary alpha-adrenergic and reduced beta-adrenergic receptors in experimental asthma. *Nature*, **1980**, 285, 569-71	50.4	173
749	Chronic idiopathic cough: a discrete clinical entity?. *Chest*, **2005**, 127, 1710-3	5.3	171
748	Parameters associated with persistent airflow obstruction in chronic severe asthma. *European Respiratory Journal*, **2004**, 24, 122-8	13.6	170
747	Increased leukotrienes in exhaled breath condensate in childhood asthma. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 1345-9	10.2	170

746	A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. *FASEB Journal*, **2003**, 17, 1298-300	0.9	168
745	Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. *Journal of Allergy and Clinical Immunology*, **2004**, 113, 1100-8	11.5	166
744	IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway. *Journal of Biological Chemistry*, **1998**, 273, 6607-10	5.4	165
743	Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 301-6	10.2	164
742	Modulation of neurogenic inflammation: novel approaches to inflammatory disease. *Trends in Pharmacological Sciences*, **1990**, 11, 185-9	13.2	164
741	Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. *Chest*, **2010**, 137, 790-6	5.3	162
740	New therapies for asthma: is there any progress?. *Trends in Pharmacological Sciences*, **2010**, 31, 335-43	13.2	161
739	Endothelium-derived relaxing factor inhibits hypoxic pulmonary vasoconstriction in rats. *The American Review of Respiratory Disease*, **1991**, 143, 32-7		161
738	Pathophysiology of asthma. *British Journal of Clinical Pharmacology*, **1996**, 42, 3-10	3.8	159
737	Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. *Biochemical and Biophysical Research Communications*, **2011**, 406, 292-8	3.4	158
736	Treatment of airway mucus hypersecretion. *Annals of Medicine*, **2006**, 38, 116-25	1.5	157
735	New molecular targets for the treatment of neutrophilic diseases. *Journal of Allergy and Clinical Immunology*, **2007**, 119, 1055-62; quiz 1063-4	11.5	156
734	New drugs for asthma. *Nature Reviews Drug Discovery*, **2004**, 3, 831-44	64.1	156
733	TGFbeta1 allele association with asthma severity. *Human Genetics*, **2001**, 109, 623-7	6.3	155
732	Prospects for new drugs for chronic obstructive pulmonary disease. *Lancet, The*, **2004**, 364, 985-96	40	152
731	Analysis of exhaled breath condensate for monitoring airway inflammation. *Trends in Pharmacological Sciences*, **2002**, 23, 232-7	13.2	152
730	Is exposure to biomass smoke the biggest risk factor for COPD globally?. *Chest*, **2010**, 138, 3-6	5.3	149
729	Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. *Journal of Biological Chemistry*, **1998**, 273, 32312-21	5.4	149

728	NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. *Journal of Immunology*, **2006**, 176, 603-15	5.3	148
727	The pharmacological properties of tiotropium. *Chest*, **2000**, 117, 63S-6S	5.3	148
726	Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. *Chest*, **2010**, 137, 1338-44	5.3	147
725	Delayed eosinophil apoptosis in asthma. *Journal of Allergy and Clinical Immunology*, **2000**, 106, 77-83	11.5	144
724	Cytokines as mediators of chronic asthma. *American Journal of Respiratory and Critical Care Medicine*, **1994**, 150, S42-9	10.2	144
723	Clinical aspects of exhaled nitric oxide. *European Respiratory Journal*, **2000**, 16, 781-92	13.6	142
722	Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. *Lancet, The*, **2001**, 357, 2007-11	40	141
721	Th2 cytokines and asthma: an introduction. *Respiratory Research*, **2001**, 2, 64-5	7.3	140
720	Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. *Molecular Pharmacology*, **2004**, 66, 1679-89	4.3	138
719	Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. *Journal of Biological Chemistry*, **1999**, 274, 19965-72	5.4	138
718	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 191, e4-e27	10.2	137
717	Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. *FASEB Journal*, **2005**, 19, 840-1	10.9	136
716	L-arginine increases exhaled nitric oxide in normal human subjects. *Clinical Science*, **1995**, 88, 135-9	6.5	135
715	Defective phagocytosis in airways disease. *Chest*, **2012**, 141, 1055-1062	5.3	134
714	Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 796-802	10.2	133
713	Analysis of expired air for oxidation products. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, S31-7	10.2	132
712	Exhaled carbon monoxide and nitric oxide in COPD. *Chest*, **2001**, 120, 496-501	5.3	130
711	Reduced histone deacetylase in COPD: clinical implications. *Chest*, **2006**, 129, 151-5	5.3	128

710	Distribution of receptor targets in the lung. *Proceedings of the American Thoracic Society*, **2004**, 1, 345-51		127
709	Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. *Journal of Allergy and Clinical Immunology*, **2015**, 136, 531-45	11.5	126
708	Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 260-7	10.2	126
707	Role of potassium channels in bronchodilator responses in human airways. *The American Review of Respiratory Disease*, **1992**, 146, 132-6		126
706	Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. *Journal of Immunology*, **2007**, 178, 2491-8	5.3	124
705	Severe asthma: advances in current management and future therapy. *Journal of Allergy and Clinical Immunology*, **2012**, 129, 48-59	11.5	123
704	Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1371-6	10.2	123
703	Single-dose slow-release aminophylline at night prevents nocturnal asthma. *Lancet, The*, **1982**, 1, 299-301	40	123
702	Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. *Biochemical and Biophysical Research Communications*, **2009**, 384, 366-71	3.4	122
701	Localization of beta-adrenoreceptors in mammalian lung by light microscopic autoradiography. *Nature*, **1982**, 299, 444-7	50.4	122
700	Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. *Life Sciences*, **1997**, 60, 67-78	6.8	121
699	Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. *Thorax*, **2011**, 66, 521-7	7.3	120
698	High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. *Respiratory Medicine*, **2003**, 97, 1299-302	4.6	120
697	Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. *The American Review of Respiratory Disease*, **1992**, 145, 1289-94		120
696	Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 1109-12	10.2	118
695	Glucocorticoids: effects on gene transcription. *Proceedings of the American Thoracic Society*, **2004**, 1, 247-54		118
694	Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 556-564	10.2	117
693	Senescence in COPD and Its Comorbidities. *Annual Review of Physiology*, **2017**, 79, 517-539	23.1	116

692	Bronchial epithelial cells: The key effector cells in the pathogenesis of chronic obstructive pulmonary disease?. *Respirology*, **2015**, 20, 722-9	3.6	116
691	CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. *Chest*, **2008**, 133, 26-33	5.3	116
690	Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia. *European Respiratory Journal*, **2003**, 21, 43-7	13.6	116
689	Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. *Journal of Leukocyte Biology*, **2004**, 76, 441-50	6.5	115
688	Quantifying proliferation of cultured human and rabbit airway smooth muscle cells in response to serum and platelet-derived growth factor. *American Journal of Respiratory Cell and Molecular Biology*, **1992**, 7, 574-81	5.7	115
687	Increased exhaled 8-isoprostane in childhood asthma. *Chest*, **2003**, 124, 25-31	5.3	114
686	Localization of muscarinic receptor subtype mRNAs in human lung. *American Journal of Respiratory Cell and Molecular Biology*, **1992**, 7, 344-8	5.7	113
685	Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. *Stem Cells*, **2013**, 31, 2813-26	5.8	112
684	Glucocorticoid resistance in asthma. *American Journal of Respiratory and Critical Care Medicine*, **1995**, 152, S125-40	10.2	112
683	Mechanisms of action of glucocorticoids in asthma. *American Journal of Respiratory and Critical Care Medicine*, **1996**, 154, S21-6; discussion S26-7	10.2	110
682	Inhaled furosemide inhibits cough induced by low chloride content solutions but not by capsaicin. *The American Review of Respiratory Disease*, **1990**, 142, 143-6		110
681	Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. *British Journal of Pharmacology*, **1991**, 103, 1339-46	8.6	110
680	Mechanisms of development of multimorbidity in the elderly. *European Respiratory Journal*, **2015**, 45, 790-806	13.6	109
679	Chronic obstructive pulmonary disease: a growing but neglected global epidemic. *PLoS Medicine*, **2007**, 4, e112	11.6	109
678	Histone deacetylation: an important mechanism in inflammatory lung diseases. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2005**, 2, 445-55	2	109
677	Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. *Journal of Allergy and Clinical Immunology*, **2005**, 116, 1028-35	11.5	109
676	Molecular mechanisms and cellular effects of glucocorticosteroids. *Immunology and Allergy Clinics of North America*, **2005**, 25, 451-68	3.3	109
675	Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. *European Respiratory Journal*, **2003**, 21, 589-93	13.6	109

674	Autoradiographic mapping of substance P receptors in lung. *European Journal of Pharmacology*, **1986**, 127, 295-6	5.3	109
673	Inhaled Corticosteroids. *Pharmaceuticals*, **2010**, 3, 514-540	5.2	108
672	Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. *Trends in Pharmacological Sciences*, **2006**, 27, 546-53	13.2	108
671	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. *European Respiratory Journal*, **2015**, 45, 879-905	13.6	107
670	Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. *Journal of Clinical Investigation*, **2011**, 121, 4289-302	15.9	107
669	p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex. *Journal of Biological Chemistry*, **2001**, 276, 30208-15	5.4	107
668	Increased p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced apoptosis in alveolar macrophages from smokers. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 724-31	10.2	107
667	Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects. *The American Review of Respiratory Disease*, **1990**, 142, 576-80		107
666	Chronic obstructive pulmonary disease: effects beyond the lungs. *PLoS Medicine*, **2010**, 7, e1000220	11.6	106
665	Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, **2009**, 6, 693-6		106
664	New treatments for COPD. *Nature Reviews Drug Discovery*, **2002**, 1, 437-46	64.1	106
663	Effects of capsazepine against capsaicin- and proton-evoked excitation of single airway C-fibres and vagus nerve from the guinea-pig. *Neuroscience*, **1995**, 67, 741-52	3.9	106
662	Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. *Journal of Allergy and Clinical Immunology*, **2004**, 114, 761-7	11.5	105
661	Effects and interactions of sensory neuropeptides on airway microvascular leakage in guinea-pigs. *British Journal of Pharmacology*, **1988**, 95, 1109-16	8.6	105
660	Severe premenstrual exacerbations of asthma: effect of intramuscular progesterone. *Lancet, The*, **1988**, 2, 370-2	40	105
659	The effect of oxidative stress on histone acetylation and IL-8 release. *Biochemical and Biophysical Research Communications*, **2003**, 301, 572-7	3.4	104
658	Effect of beta-agonists on inflammatory cells. *Journal of Allergy and Clinical Immunology*, **1999**, 104, S10-7	11.5	104
657	Effects of tachykinins on mucus secretion in human bronchi in vitro. *European Journal of Pharmacology*, **1989**, 174, 283-6	5.3	104

656	Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma. *American Journal of Respiratory Cell and Molecular Biology*, **2008**, 39, 543-50	5.7	103
655	Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. *Respiratory Medicine*, **2005**, 99, 703-10	4.6	103
654	STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. *European Respiratory Journal*, **2004**, 24, 78-85	13.6	103
653	Theophylline in chronic obstructive pulmonary disease: new horizons. *Proceedings of the American Thoracic Society*, **2005**, 2, 334-9; discussion 340-1		102
652	The role of oxidative stress in chronic obstructive pulmonary disease. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2004**, 1, 255-77	2	101
651	The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. *The American Review of Respiratory Disease*, **1984**, 130, 162-6		101
650	Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. *Journal of Allergy and Clinical Immunology*, **2010**, 126, 754-762.e1	11.5	100
649	Burden and pathogenesis of chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, **2009**, 6, 524-6		100
648	Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex. *British Journal of Pharmacology*, **1986**, 88, 741-5	8.6	99
647	Alternative mechanisms for tiotropium. *Pulmonary Pharmacology and Therapeutics*, **2009**, 22, 533-42	3.5	98
646	Inhaled corticosteroids in COPD: a controversy. *Respiration*, **2010**, 80, 89-95	3.7	97
645	Greater effect of inhaled budesonide on adenosine 5'-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. *The American Review of Respiratory Disease*, **1992**, 146, 560-4		97
644	Superinduction of COX-2 mRNA by cycloheximide and interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation. *FEBS Letters*, **1997**, 418, 135-8	3.8	96
643	Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis. *Journal of Clinical Immunology*, **2015**, 35, 1-10	5.7	95
642	Histone deacetylase-2 and airway disease. *Therapeutic Advances in Respiratory Disease*, **2009**, 3, 235-43	4.9	95
641	The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans. *The American Review of Respiratory Disease*, **1989**, 139, 446-9		94
640	Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 324, 270-5	4.7	93
639	Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. *Life Sciences*, **1995**, 56, 853-9	6.8	93

638	Histamine H3-receptors inhibit cholinergic neurotransmission in guinea-pig airways. *British Journal of Pharmacology*, **1989**, 97, 13-5	8.6	93
637	Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 321, 734-42	4.7	92
636	Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 173, 398-406	10.2	92
635	Cytokine modulators as novel therapies for asthma. *Annual Review of Pharmacology and Toxicology*, **2002**, 42, 81-98	17.9	92
634	Transcription factors in airway diseases. *Laboratory Investigation*, **2006**, 86, 867-72	5.9	91
633	Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. *Lancet, The*, **2000**, 355, 1675-9	40	91
632	The effect of endogenous nitric oxide on neurogenic plasma exudation in guinea-pig airways. *European Journal of Pharmacology*, **1992**, 221, 385-8	5.3	90
631	Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. *Thorax*, **2010**, 65, 263-7	7.3	89
630	Emerging pharmacotherapies for COPD. *Chest*, **2008**, 134, 1278-1286	5.3	89
629	Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. *Chest*, **2000**, 117, 1085-9	5.3	89
628	Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. *Clinical Science*, **1996**, 90, 301-6	6.5	89
627	A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-Ƀ inhibition. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, 345, 76-84	4.7	88
626	Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. *Pulmonary Pharmacology and Therapeutics*, **2010**, 23, 165-71	3.5	88
625	Corticosteroid resistance in airway disease. *Proceedings of the American Thoracic Society*, **2004**, 1, 264-8		88
624	Effect of dexamethasone on interleukin-1beta-(IL-1beta)-induced nuclear factor-kappaB (NF-kappaB) and kappaB-dependent transcription in epithelial cells. *FEBS Journal*, **1998**, 254, 81-9		87
623	Small airways in COPD. *New England Journal of Medicine*, **2004**, 350, 2635-7	59.2	87
622	Faster rise of exhaled breath temperature in asthma: a novel marker of airway inflammation?. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 181-4	10.2	87
621	Anticholinergic blockade of beta-blocker-induced bronchoconstriction. *The American Review of Respiratory Disease*, **1989**, 139, 1390-4		87

620	Cytokine-directed therapies for the treatment of chronic airway diseases. *Cytokine and Growth Factor Reviews*, **2003**, 14, 511-22	17.9	86
619	Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. *British Journal of Pharmacology*, **1999**, 127, 1003-11	8.6	86
618	Exhaled nitric oxide is increased in active fibrosing alveolitis. *Chest*, **1999**, 115, 1352-6	5.3	86
617	Biochemical basis of asthma therapy. *Journal of Biological Chemistry*, **2011**, 286, 32899-905	5.4	85
616	IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. *FEBS Letters*, **2003**, 547, 75-9	3.8	85
615	Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. *PLoS ONE*, **2012**, 7, e41582	3.7	83
614	Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. *Journal of Allergy and Clinical Immunology*, **2006**, 117, 1484-92	11.5	83
613	Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis. *European Respiratory Journal*, **2001**, 17, 1201-7	13.6	83
612	A comparison of beta-adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle. *American Journal of Respiratory Cell and Molecular Biology*, **1992**, 6, 647-51	5.7	83
611	Developmental changes in endothelium-dependent pulmonary vasodilatation in pigs. *British Journal of Pharmacology*, **1992**, 106, 324-30	8.6	83
610	Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization. *Journal of Biological Chemistry*, **1998**, 273, 20575-88	5.4	82
609	Mitochondria, telomeres and cell senescence: Implications for lung ageing and disease. *Pharmacology & Therapeutics*, **2018**, 183, 34-49	13.9	81
608	Against the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseases. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 240-3; discussion 243-4	10.2	81
607	Inhibition of neurogenic plasma exudation in guinea-pig airways by CP-96,345, a new non-peptide NK1 receptor antagonist. *British Journal of Pharmacology*, **1992**, 105, 261-2	8.6	81
606	New directions in allergic diseases: mechanism-based anti-inflammatory therapies. *Journal of Allergy and Clinical Immunology*, **2000**, 106, 5-16	11.5	80
605	Neuropeptides and asthma. *The American Review of Respiratory Disease*, **1991**, 143, S28-32		80
604	Autoradiographic localization of calcitonin gene-related peptide (CGRP) binding sites in human and guinea pig lung. *Peptides*, **1988**, 9, 957-63	3.8	80
603	Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. *Thorax*, **2014**, 69, 516-24	7.3	79

602	Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. *British Journal of Pharmacology*, **1997**, 122, 149-57	8.6	79
601	Effect of antiasthma drugs on microvascular leakage in guinea pig airways. *The American Review of Respiratory Disease*, **1989**, 139, 416-21		79
600	The action of a potassium channel activator, BRL 38227 (lemakalim), on human airway smooth muscle. *The American Review of Respiratory Disease*, **1990**, 142, 1384-9		79
599	Corticosteroid inhibition of airway microvascular leakage. *The American Review of Respiratory Disease*, **1991**, 143, 605-9		79
598	Sensory neuropeptide effects in human skin. *British Journal of Pharmacology*, **1987**, 92, 781-8	8.6	79
597	Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2003**, 284, L279-89	5.8	78
596	Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma. *Clinical Pharmacology and Therapeutics*, **2009**, 86, 49-53	6.1	77
595	Opioid modulation of non-cholinergic neural bronchoconstriction in guinea-pig in vivo. *British Journal of Pharmacology*, **1988**, 95, 413-8	8.6	77
594	Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. *Pharmacological Reviews*, **2016**, 68, 788-815	22.5	77
593	Theobromine inhibits sensory nerve activation and cough. *FASEB Journal*, **2005**, 19, 231-3	0.9	76
592	Expression of heme oxygenase in human airway epithelial cells. *American Journal of Respiratory Cell and Molecular Biology*, **2001**, 24, 295-303	5.7	76
591	Exhaled carbon monoxide in childhood asthma. *Journal of Pediatrics*, **1999**, 135, 569-74	3.6	76
590	Drugs for asthma. *British Journal of Pharmacology*, **2006**, 147 Suppl 1, S297-303	8.6	75
589	Ozone induction of cytokine-induced neutrophil chemoattractant (CINC) and nuclear factor-kappa b in rat lung: inhibition by corticosteroids. *FEBS Letters*, **1996**, 379, 265-8	3.8	75
588	Calcitonin gene-related peptide (CGRP) is a potent non-endothelium-dependent inhibitor of coronary vasomotor tone. *British Journal of Pharmacology*, **1987**, 92, 789-94	8.6	75
587	Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 21-30	10.2	74
586	New drugs for exacerbations of chronic obstructive pulmonary disease. *Lancet, The*, **2009**, 374, 744-55	40	74
585	Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation. *British Journal of Pharmacology*, **2003**, 140, 261-8	8.6	74

584	The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes. *British Journal of Pharmacology*, **2000**, 130, 1353-61	8.6	74
583	Loop diuretics inhibit cholinergic and noncholinergic nerves in guinea pig airways. *The American Review of Respiratory Disease*, **1991**, 143, 1340-4		74
582	Effect of hydrogen peroxide on guinea-pig tracheal smooth muscle in vitro: role of cyclo-oxygenase and airway epithelium. *British Journal of Pharmacology*, **1989**, 98, 325-30	8.6	74
581	New Therapies for Asthma and Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 159-166	10.2	73
580	Effects of aerosolized adenosine 5'-triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. *Chest*, **2005**, 128, 1905-9	5.3	73
579	Airway neuropeptides and asthma. *Trends in Pharmacological Sciences*, **1987**, 8, 24-27	13.2	73
578	Role of GATA-3 in allergic diseases. *Current Molecular Medicine*, **2008**, 8, 330-4	2.5	72
577	Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. *Journal of Allergy and Clinical Immunology*, **2006**, 118, 347-53	11.5	72
576	Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. *Current Allergy and Asthma Reports*, **2003**, 3, 121-9	5.6	72
575	Superinduction of NF-kappa B by actinomycin D and cycloheximide in epithelial cells. *Biochemical and Biophysical Research Communications*, **1996**, 218, 518-23	3.4	72
574	Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. *PLoS Medicine*, **2009**, 6, e1000076	11.6	71
573	Neurogenic inflammation and asthma. *Journal of Asthma*, **1992**, 29, 165-80	1.9	71
572	Reduction of nocturnal asthma by an inhaled anticholinergic drug. *Chest*, **1986**, 90, 485-8	5.3	71
571	Brd4 is essential for IL-1□nduced inflammation in human airway epithelial cells. *PLoS ONE*, **2014**, 9, e95057	3.7	70
570	Passive smoking impairs histone deacetylase-2 in children with severe asthma. *Chest*, **2014**, 145, 305-312	5.3	70
569	Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-□ *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 337, 465-70	4.7	70
568	The ADMIT series - Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. *Primary Care Respiratory Journal: Journal of the General Practice Airways Group*, **2010**, 19, 10-20		70
567	Release of nerve growth factor by human pulmonary epithelial cells: role in airway inflammatory diseases. *European Journal of Pharmacology*, **2001**, 424, 159-62	5.3	70

566	Exhaled markers of inflammation. *Current Opinion in Allergy and Clinical Immunology*, **2001**, 1, 217-224	3.3	70
565	The effects of activated eosinophils and neutrophils on guinea pig airway epithelium in vitro. *American Journal of Respiratory Cell and Molecular Biology*, **1990**, 2, 341-53	5.7	70
564	MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. *Histopathology*, **2009**, 55, 321-31	7.3	69
563	Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis. *Free Radical Biology and Medicine*, **2008**, 45, 913-9	7.8	69
562	Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. *Journal of Applied Physiology*, **2003**, 95, 2106-12	3.7	69
561	Inhibitors of protein kinase C (PKC) prevent activated transcription: role of events downstream of NF-kappaB DNA binding. *Journal of Biological Chemistry*, **2004**, 279, 18457-66	5.4	69
560	Expression and regulation of inducible nitric oxide synthase from human primary airway epithelial cells. *American Journal of Respiratory Cell and Molecular Biology*, **2002**, 26, 144-51	5.7	69
559	Questions about inhaled beta 2-adrenoceptor agonists in asthma. *Trends in Pharmacological Sciences*, **1992**, 13, 20-3	13.2	69
558	IL-1 beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter. *Journal of Immunology*, **2006**, 177, 7173-83	5.3	68
557	Exhaled nitric oxide and hydrogen peroxide concentrations in asthmatic smokers. *Respiration*, **2004**, 71, 463-8	3.7	68
556	Oxidative stress-based therapeutics in COPD. *Redox Biology*, **2020**, 33, 101544	11.3	68
555	Glucocorticosteroids. *Handbook of Experimental Pharmacology*, **2017**, 237, 93-115	3.2	67
554	Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. *Chest*, **2009**, 135, 1513-1520	5.3	67
553	Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. *Molecular Pharmacology*, **2006**, 70, 697-705	4.3	67
552	Modulation of non-adrenergic, non-cholinergic neural bronchoconstriction in guinea-pig airways via GABAB-receptors. *British Journal of Pharmacology*, **1989**, 97, 1225-31	8.6	67
551	Neuropeptides in human airways: function and clinical implications. *The American Review of Respiratory Disease*, **1987**, 136, S77-83		67
550	Mu-opioid receptors modulate non-cholinergic constrictor nerves in guinea-pig airways. *European Journal of Pharmacology*, **1987**, 141, 519-22	5.3	67
549	Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. *European Respiratory Journal*, **1997**, 10, 1483-8	13.6	66

548	Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. *Chest*, **2007**, 131, 1353-62	5.3	66
547	Changes in exhaled carbon monoxide and nitric oxide levels following allergen challenge in patients with asthma. *European Respiratory Journal*, **1999**, 13, 48-52	13.6	66
546	Impaired macrophage phagocytosis of bacteria in severe asthma. *Respiratory Research*, **2014**, 15, 72	7.3	65
545	Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor B and c-Jun N-terminal kinase activation. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 1075-1085.e6	11.5	65
544	Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. *British Journal of Pharmacology*, **1999**, 127, 413-20	8.6	65
543	Facilitation by tachykinins of neurotransmission in guinea-pig pulmonary parasympathetic nerves. *British Journal of Pharmacology*, **1989**, 97, 274-80	8.6	65
542	Probiotics in the management of lung diseases. *Mediators of Inflammation*, **2013**, 2013, 751068	4.3	64
541	Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. *Journal of Allergy and Clinical Immunology*, **1998**, 101, S427-33	11.5	64
540	Evidence for two platelet activating factor receptors on eosinophils: dissociation between PAF-induced intracellular calcium mobilization degranulation and superoxides anion generation in eosinophils. *Biochemical and Biophysical Research Communications*, **1989**, 162, 511-21	3.4	64
539	The prevalence of small airways disease in adult asthma: A systematic literature review. *Respiratory Medicine*, **2016**, 116, 19-27	4.6	64
538	Restoration of Corticosteroid Sensitivity in Chronic Obstructive Pulmonary Disease by Inhibition of Mammalian Target of Rapamycin. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 143-53	10.2	63
537	Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. *Annals of Medicine*, **2012**, 44, 146-56	1.5	63
536	Exhaled 8-isoprostane in childhood asthma. *Respiratory Research*, **2005**, 6, 79	7.3	63
535	Formoterol attenuates neutrophilic airway inflammation in asthma. *Chest*, **2005**, 128, 1936-42	5.3	63
534	Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response. *Antioxidants and Redox Signaling*, **2005**, 7, 144-52	8.4	63
533	Correlation of exhaled breath temperature with bronchial blood flow in asthma. *Respiratory Research*, **2005**, 6, 15	7.3	62
532	p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism. *British Journal of Pharmacology*, **2000**, 131, 1143-53	8.6	62
531	Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. *British Journal of Pharmacology*, **1999**, 127, 1151-8	8.6	62

530	The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. *Life Sciences*, **1994**, 55, 1147-53	6.8	62
529	Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. *British Journal of Pharmacology*, **2002**, 135, 987-96	8.6	61
528	An inhaled steroid improves markers of airway inflammation in patients with mild asthma. *European Respiratory Journal*, **1998**, 12, 1084-8	13.6	61
527	Localization of beta 2-adrenoceptor messenger RNA in human and rat lung using in situ hybridization: correlation with receptor autoradiography. *European Journal of Pharmacology*, **1991**, 206, 133-8		61
526	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet, The*, **2021**, 398, 843-855	40	61
525	Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. *Chest*, **2005**, 128, 1974-9	5.3	60
524	Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation. *European Journal of Pharmacology*, **2001**, 429, 327-34	5.3	60
523	Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. *European Journal of Pharmacology*, **1995**, 289, 275-81		60
522	Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. *British Journal of Clinical Pharmacology*, **1989**, 27, 831-6	3.8	60
521	Inflammatory endotypes in COPD. *Allergy: European Journal of Allergy and Clinical Immunology*, **2019**, 74, 1249-1256	9.3	59
520	Klotho expression is reduced in COPD airway epithelial cells: effects on inflammation and oxidant injury. *Clinical Science*, **2015**, 129, 1011-23	6.5	59
519	Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma. *PLoS ONE*, **2011**, 6, e27627	3.7	59
518	Effect of theophylline and adenosine on eosinophil function. *The American Review of Respiratory Disease*, **1989**, 140, 327-33		59
517	New therapies for chronic obstructive pulmonary disease. *Medical Principles and Practice*, **2010**, 19, 330-8	2.1	58
516	Interactions of glucocorticoids and beta 2-agonists. *European Respiratory Journal*, **1996**, 9, 160-8	13.6	58
515	Circadian variation in airway function. *American Journal of Medicine*, **1985**, 79, 5-9	2.4	58
514	Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 324, 306-12	4.7	57
513	Cytokine-directed therapies for asthma. *Journal of Allergy and Clinical Immunology*, **2001**, 108, S72-6	11.5	57

512	Cholinergic control of airway smooth muscle. *The American Review of Respiratory Disease*, **1987**, 136, S42-5		57
511	Radioligand binding of antagonists of platelet-activating factor to intact human platelets. *FEBS Letters*, **1988**, 228, 285-9	3.8	57
510	Comparison of neurokinin A and substance P on cardiovascular and airway function in man. *British Journal of Clinical Pharmacology*, **1988**, 25, 273-5	3.8	57
509	Small airways: an important but neglected target in the treatment of obstructive airway diseases. *Trends in Pharmacological Sciences*, **2008**, 29, 340-5	13.2	56
508	Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. *European Respiratory Journal*, **2001**, 18, 466-73	13.6	56
507	Effect of interleukin-1 beta on airway hyperresponsiveness and inflammation in sensitized and nonsensitized Brown-Norway rats. *Journal of Allergy and Clinical Immunology*, **1994**, 93, 464-9	11.5	56
506	Circulatory and respiratory effects of infused adenosine in conscious man. *British Journal of Clinical Pharmacology*, **1987**, 24, 309-17	3.8	55
505	Microarray analysis of long non-coding RNAs in COPD lung tissue. *Inflammation Research*, **2015**, 64, 119-26	7.2	54
504	Alternate COX-2 transcripts are differentially regulated: implications for post-transcriptional control. *Biochemical and Biophysical Research Communications*, **1997**, 234, 85-9	3.4	54
503	Future treatments for chronic obstructive pulmonary disease and its comorbidities. *Proceedings of the American Thoracic Society*, **2008**, 5, 857-64		54
502	Nitric oxide synthase activity is elevated in inflammatory lung disease in humans. *European Journal of Pharmacology*, **1995**, 283, 255-8	5.3	54
501	Endogenous tachykinins facilitate transmission through parasympathetic ganglia in guinea-pig trachea. *British Journal of Pharmacology*, **1993**, 109, 751-9	8.6	54
500	Airway smooth muscle and disease workshop: epithelial mediators. *The American Review of Respiratory Disease*, **1987**, 136, S32-5		54
499	Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. *Respiratory Research*, **2013**, 14, 137	7.3	53
498	A comprehensive analysis of oxidative stress in the ozone-induced lung inflammation mouse model. *Clinical Science*, **2014**, 126, 425-40	6.5	53
497	p38 mitogen-activated protein kinase-inhibition by long-acting adrenergic agonists reversed steroid insensitivity in severe asthma. *Molecular Pharmacology*, **2011**, 80, 1128-35	4.3	53
496	Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD. *Chest*, **2016**, 149, 62-73	5.3	52
495	Standardised exhaled breath collection for the measurement of exhaled volatile organic compounds by proton transfer reaction mass spectrometry. *BMC Pulmonary Medicine*, **2013**, 13, 43	3.5	52

494	Theophylline. *Pharmaceuticals*, **2010**, 3, 725-747	5.2	52
493	Is immunotherapy for asthma worthwhile?. *New England Journal of Medicine*, **1996**, 334, 531-2	59.2	52
492	Effect of CP-96,345, a non-peptide NK1 receptor antagonist, against substance P-, bradykinin- and allergen-induced airway microvascular leakage and bronchoconstriction in the guinea pig. *European Journal of Pharmacology*, **1993**, 231, 31-8	5.3	52
491	Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 845-855	10.2	51
490	Current therapies for asthma. Promise and limitations. *Chest*, **1997**, 111, 17S-26S	5.3	51
489	Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. *Chest*, **2008**, 134, 1192-1199	5.3	51
488	Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils. *Chest*, **2007**, 132, 98-105	5.3	51
487	Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, **2004**, 1, 191-9		51
486	Pathophysiology and clinical presentations of cough????. *Journal of Allergy and Clinical Immunology*, **1996**, 98, S91-S97	11.5	51
485	Autoradiographic mapping of beta-adrenoceptors in human skin. *Archives of Dermatological Research*, **1996**, 288, 549-53	3.3	51
484	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. *European Respiratory Review*, **2015**, 24, 159-72	9.8	50
483	New perspectives in pharmacological treatment of mild persistent asthma. *Drug Discovery Today*, **2011**, 16, 1084-91	8.8	50
482	Modulation of cholinergic neurotransmission in guinea-pig trachea by neuropeptide Y. *British Journal of Pharmacology*, **1988**, 93, 672-8	8.6	50
481	Defective bacterial phagocytosis is associated with dysfunctional mitochondria in COPD macrophages. *European Respiratory Journal*, **2019**, 54,	13.6	49
480	Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. *Respiratory Research*, **2014**, 15, 114	7.3	49
479	The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. *Journal of Allergy and Clinical Immunology*, **2011**, 128, 800-807.e9	11.5	49
478	Characterization of T lymphocytes in chronic obstructive pulmonary disease. *PLoS Medicine*, **2004**, 1, e20	11.6	49
477	Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1602-9	10.2	49

476	Molecular regulation of granulocyte macrophage colony-stimulating factor in human lung epithelial cells by interleukin (IL)-1beta, IL-4, and IL-13 involves both transcriptional and post-transcriptional mechanisms. *American Journal of Respiratory Cell and Molecular Biology*, **2000**, 22, 582-9	5.7	49
475	Effect of inhaled corticosteroids on bones and growth. *European Respiratory Journal*, **1998**, 11, 1167-77	13.6	49
474	The effect of platelet activating factor on pulmonary beta-adrenoceptors. *British Journal of Pharmacology*, **1987**, 90, 709-15	8.6	49
473	Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. *European Respiratory Journal*, **2017**, 49,	13.6	48
472	ERS/ATS workshop report on respiratory health effects of household air pollution. *European Respiratory Journal*, **2018**, 51,	13.6	48
471	Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. *European Journal of Pharmacology*, **2011**, 670, 244-51	5.3	47
470	Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes. *Cell Biochemistry and Biophysics*, **1998**, 29, 179-201	3.2	47
469	Bradykinin-induced plasma exudation in guinea-pig airways: involvement of platelet activating factor. *British Journal of Pharmacology*, **1990**, 101, 739-45	8.6	47
468	Novel signal transduction modulators for the treatment of airway diseases **2006**, 109, 238-45		46
467	Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. *International Journal of Immunopathology and Pharmacology*, **2007**, 20, 753-63	3	46
466	Endogenous nitric oxide modulates adrenergic neural vasoconstriction in guinea-pig pulmonary artery. *British Journal of Pharmacology*, **1991**, 104, 565-9	8.6	46
465	Effect of tachykinins in small human airways. *Neuropeptides*, **1991**, 19, 157-61	3.3	46
464	Corticosteroids, IgE, and atopy. *Journal of Clinical Investigation*, **2001**, 107, 265-6	15.9	46
463	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 320, 1548-1559	27.4	46
462	Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. *Chest*, **2015**, 148, 1164-76	5.3	45
461	Regulation of eosinophil apoptosis by nitric oxide: Role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5. *Journal of Allergy and Clinical Immunology*, **2003**, 112, 93-101	11.5	45
460	COPD--a neglected disease. *Lancet, The*, **2004**, 364, 564-5	40	45
459	Role of nitric oxide and guanosine 3',5'-cyclic monophosphate in mediating nonadrenergic, noncholinergic relaxation in guinea-pig pulmonary arteries. *British Journal of Pharmacology*, **1992**, 107, 861-6	8.6	45

458	Hydrogen peroxide in exhaled breath condensate in patients with asthma: a promising biomarker?. *Chest*, **2011**, 140, 108-116	5.3	44
457	Oxidative stress modulates theophylline effects on steroid responsiveness. *Biochemical and Biophysical Research Communications*, **2008**, 377, 797-802	3.4	44
456	ICAM-1 expression is highly NF-kappaB-dependent in A549 cells. No role for ERK and p38 MAPK. *FEBS Journal*, **2004**, 271, 785-91		44
455	Attenuated production of intracellular IL-10 and IL-12 in monocytes from patients with severe asthma. *Clinical Immunology*, **2002**, 102, 258-66	9	44
454	Inhibitory role of endothelium-derived relaxing factor in rat and human pulmonary arteries. *British Journal of Pharmacology*, **1990**, 101, 166-70	8.6	44
453	Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. *Drugs of Today*, **2002**, 38, 585-600		44
452	Inducible nitric oxide synthase after sensitization and allergen challenge of Brown Norway rat lung. *British Journal of Pharmacology*, **1997**, 121, 1241-6	8.6	43
451	Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids. *Journal of Allergy and Clinical Immunology*, **2008**, 121, 43-50	11.5	43
450	Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. *Respiratory Research*, **2004**, 5, 17	7.3	43
449	Is asthma a nervous disease? The Parker B. Francis Lectureship. *Chest*, **1995**, 107, 119S-125S	5.3	43
448	The effect of alcohol ingestion on exhaled nitric oxide. *European Respiratory Journal*, **1996**, 9, 1130-3	13.6	43
447	Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition. *British Journal of Pharmacology*, **2012**, 167, 775-86	8.6	42
446	Effects of aminoguanidine, an inhibitor of inducible nitric oxide synthase, on nitric oxide production and its metabolites in healthy control subjects, healthy smokers, and COPD patients. *Chest*, **2009**, 135, 353-367	5.3	42
445	New therapies for asthma. *Trends in Molecular Medicine*, **2006**, 12, 515-20	11.5	42
444	Evidence for two P2-purinoceptor subtypes in human small pulmonary arteries. *British Journal of Pharmacology*, **1989**, 98, 1014-20	8.6	42
443	Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography. *British Journal of Pharmacology*, **1986**, 89, 157-62	8.6	42
442	Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. *European Respiratory Journal*, **2016**, 47, 1093-102	13.6	41
441	Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression. *Journal of Immunology*, **2014**, 192, 4913-4920	5.3	41

440	Actions of methoctramine, a muscarinic M2 receptor antagonist, on muscarinic and nicotinic cholinoceptors in guinea-pig airways in vivo and in vitro. *British Journal of Pharmacology*, **1992**, 105, 107-12	8.6	41
439	The effect of platelet-activating factor on histamine and muscarinic receptor function in guinea pig airways. *The American Review of Respiratory Disease*, **1988**, 137, 1317-22		41
438	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. *PLoS ONE*, **2016**, 11, e0163139	3.7	41
437	MicroRNA-570 is a novel regulator of cellular senescence and inflammaging. *FASEB Journal*, **2019**, 33, 1605-1616	0.9	41
436	Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism. *British Journal of Pharmacology*, **2017**, 174, 2043-2059	8.6	40
435	Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 207-16.e1-11	11.5	40
434	Hypoxia-inducible factor 1alpha induces corticosteroid-insensitive inflammation via reduction of histone deacetylase-2 transcription. *Journal of Biological Chemistry*, **2009**, 284, 36047-36054	5.4	40
433	Modulation of airway smooth muscle beta-adrenoceptor function by a muscarinic agonist. *Life Sciences*, **1994**, 54, 185-91	6.8	40
432	Chairman's Summary. *The American Review of Respiratory Disease*, **1990**, 141, S97-S98		40
431	Biochemistry of asthma. *Trends in Biochemical Sciences*, **1991**, 16, 365-9	10.3	40
430	Tumour necrosis factor-□ regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-B and AP-1. *PLoS ONE*, **2014**, 9, e90298	3.7	40
429	Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD. *Thorax*, **2013**, 68, 330-7	7.3	39
428	Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E release. *FEBS Journal*, **2004**, 271, 4042-52		39
427	Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. *Expert Opinion on Therapeutic Targets*, **2005**, 9, 1111-21	6.4	39
426	Regulation of NANC neural bronchoconstriction in vivo in the guinea-pig: involvement of nitric oxide, vasoactive intestinal peptide and soluble guanylyl cyclase. *British Journal of Pharmacology*, **1993**, 108, 228-35	8.6	39
425	Glucocorticoids. *Chemical Immunology and Allergy*, **2014**, 100, 311-6		38
424	Exhaled carbon monoxide in asthmatics: a meta-analysis. *Respiratory Research*, **2010**, 11, 50	7.3	38
423	Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. *Journal of Allergy and Clinical Immunology*, **1997**, 99, 58-64	11.5	38

422	Frontrunners in novel pharmacotherapy of COPD. *Current Opinion in Pharmacology*, **2008**, 8, 300-7	5.1	38
421	Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia. *Chest*, **2003**, 124, 633-8	5.3	38
420	Therapy of chronic obstructive pulmonary disease **2003**, 97, 87-94		38
419	Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. *British Journal of Pharmacology*, **2005**, 145, 114-22	8.6	38
418	Tiotropium bromide. *Expert Opinion on Investigational Drugs*, **2001**, 10, 733-40	5.9	38
417	Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors. *Biochemical Journal*, **1996**, 318 (Pt 2), 425-36	3.8	38
416	Effects of two novel tachykinin antagonists, FK224 and FK888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guinea-pigs in vivo. *British Journal of Pharmacology*, **1993**, 108, 844-51	8.6	38
415	Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 1166-73	11.5	37
414	Regulation of IL-17 in chronic inflammation in the human lung. *Clinical Science*, **2011**, 120, 515-24	6.5	37
413	Inhibitory cytokines in asthma. *Trends in Molecular Medicine*, **1998**, 4, 452-8		37
412	Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. *American Journal of Respiratory Cell and Molecular Biology*, **2004**, 30, 342-9	5.7	37
411	Does exhaled nitric oxide reflect asthma control? Yes, it does!. *American Journal of Respiratory and Critical Care Medicine*, **2001**, 164, 727-8	10.2	37
410	Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study. *Respiratory Medicine*, **2001**, 95, 505-12	4.6	37
409	Effects of dexamethasone on cytokine and phorbol ester stimulated c-Fos and c-Jun DNA binding and gene expression in human lung. *European Respiratory Journal*, **1994**, 7, 2117-23	13.6	37
408	Dilemmas, Confusion, and Misconceptions Related to Small Airways Directed Therapy. *Chest*, **2017**, 151, 1345-1355	5.3	36
407	Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells. *PLoS ONE*, **2015**, 10, e0128757	3.7	36
406	The role of IkappaB kinase 2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-gamma-stimulated human bronchial epithelial cells. *Journal of Immunology*, **2007**, 179, 6237-45	5.3	36
405	Glucocorticoid inhibition of granulocyte macrophage-colony-stimulating factor from T cells is independent of control by nuclear factor-kappaB and conserved lymphokine element 0. *American Journal of Respiratory Cell and Molecular Biology*, **2004**, 30, 555-63	5.7	36

404	Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. *European Journal of Pharmacology*, **2002**, 436, 165-72	5.3	36
403	Evidence that the anti-spasmogenic effect of the beta-adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase. *British Journal of Pharmacology*, **2001**, 133, 1201-12	8.6	36
402	Transcriptional down-regulation of m2 muscarinic receptor gene expression in human embryonic lung (HEL 299) cells by protein kinase C. *Journal of Biological Chemistry*, **1995**, 270, 7213-8	5.4	36
401	PAF antagonists. Their potential therapeutic role in asthma. *Drugs*, **1988**, 35, 93-103	12.1	36
400	Receptor heterodimerization: a new level of cross-talk. *Journal of Clinical Investigation*, **2006**, 116, 1210-2	15.9	36
399	Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. *Chest*, **2016**, 150, 123-30	5.3	36
398	Increased corticosteroid sensitivity by a long acting β2 agonist formoterol via β2 adrenoceptor independent protein phosphatase 2A activation. *Pulmonary Pharmacology and Therapeutics*, **2012**, 25, 201-7	3.5	35
397	Prevention of death in COPD. *New England Journal of Medicine*, **2007**, 356, 2211; author reply 2213-4	59.2	35
396	Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?. *Current Opinion in Pharmacology*, **2003**, 3, 270-6	5.1	35
395	Anti-IgE therapy in asthma: rationale and therapeutic potential. *International Archives of Allergy and Immunology*, **2000**, 123, 196-204	3.7	35
394	Contribution of intercellular-adhesion molecule-1 in allergen-induced airway hyperresponsiveness and inflammation in sensitised brown-Norway rats. *International Archives of Allergy and Immunology* , **1994**, 104, 291-5	3.7	35
393	Characterization of platelet-activating factor-induced elevation of cytosolic free calcium concentration in eosinophils. *FEBS Letters*, **1989**, 243, 41-6	3.8	35
392	The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects. *British Journal of Clinical Pharmacology*, **1987**, 23, 91-3	3.8	35
391	Effect of a Paf antagonist, WEB 2086, on airway microvascular leakage in the guinea-pig and platelet aggregation in man. *British Journal of Pharmacology*, **1988**, 94, 164-8	8.6	35
390	Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease. *Drugs of Today*, **2004**, 40, 55-69		35
389	Decreased Serum Sirtuin-1 in COPD. *Chest*, **2017**, 152, 343-352	5.3	34
388	Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma. *Journal of Allergy and Clinical Immunology*, **2009**, 123, 239-48	11.5	34
387	Rapid effect of inhaled ciclesonide in asthma: a randomized, placebo-controlled study. *Chest*, **2008**, 134, 740-745	5.3	34

386	Achieving asthma control. *Current Medical Research and Opinion*, **2005**, 21 Suppl 4, S5-9	2.5	34
385	Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. *European Respiratory Journal*, **2003**, 22, 457-61	13.6	34
384	Mitogen-activated protein kinases mediate peroxynitrite-induced cell death in human bronchial epithelial cells. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2003**, 284, L1112-20	5.8	34
383	Selective inhibition of a high affinity type IV cyclic AMP phosphodiesterase in bovine trachealis by AH 21-132. Relevance to the spasmolytic and anti-spasmogenic actions of AH 21-132 in the intact tissue. *Biochemical Pharmacology*, **1991**, 42, 663-77	6	34
382	Effect of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects. *British Journal of Clinical Pharmacology*, **1988**, 26, 65-72	3.8	34
381	Importin-7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity. *FASEB Journal*, **2013**, 27, 4510-9	0.9	33
380	Sputum plasminogen activator inhibitor-1 elevation by oxidative stress-dependent nuclear factor-B activation in COPD. *Chest*, **2013**, 144, 515-521	5.3	33
379	Rescue treatment in asthma. More than as-needed bronchodilation. *Chest*, **2009**, 135, 1628-1633	5.3	33
378	Effect of an inducible nitric oxide synthase inhibitor on differential flow-exhaled nitric oxide in asthmatic patients and healthy volunteers. *Chest*, **2007**, 132, 581-8	5.3	33
377	The role of anticholinergics in chronic obstructive pulmonary disease. *The American Journal of Medicine: Supplement*, **2004**, 117 Suppl 12A, 24S-32S		33
376	Pleiotropic role of lyn kinase in leukotriene B4-induced eosinophil activation. *Blood*, **2000**, 95, 3541-3547	2.2	33
375	Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. *British Journal of Pharmacology*, **1996**, 117, 79-86	8.6	33
374	Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2017**, 313, L230-L239	5.8	32
373	Increased neutrophil gelatinase-associated lipocalin (NGAL) promotes airway remodelling in chronic obstructive pulmonary disease. *Clinical Science*, **2017**, 131, 1147-1159	6.5	32
372	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. *European Respiratory Review*, **2018**, 27,	9.8	32
371	Downregulation of MicroRNA-126 Augments DNA Damage Response in Cigarette Smokers and Patients with Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 665-668	10.2	32
370	Toll-like receptor 3 stimulation causes corticosteroid-refractory airway neutrophilia and hyperresponsiveness in mice. *Chest*, **2013**, 144, 99-105	5.3	32
369	Prostaglandin E2 suppression of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by interacting with prostanoid receptors of the EP3-subtype. *British Journal of Pharmacology*, **1998**, 123, 1246-52	8.6	32

368	Ceramide induction of COX-2 and PGE(2) in pulmonary A549 cells does not involve activation of NF-kappaB. *Biochemical and Biophysical Research Communications*, **2000**, 277, 675-9	3.4	32
367	Effect of infused adenosine on cardiac output and systemic resistance in normal subjects. *British Journal of Clinical Pharmacology*, **1989**, 27, 165-71	3.8	32
366	Extracellular Adenosine 5′-Triphosphate in Obstructive Airway Diseases. *Chest*, **2016**, 150, 908-915	5.3	31
365	COPD: is there light at the end of the tunnel?. *Current Opinion in Pharmacology*, **2004**, 4, 263-72	5.1	31
364	PAF closely mimics pathology of asthma. *Trends in Pharmacological Sciences*, **1987**, 8, 285-287	13.2	31
363	Inflammatory mechanisms and nocturnal asthma. *American Journal of Medicine*, **1988**, 85, 64-70	2.4	31
362	TGF- Signaling Pathways in Different Compartments of the Lower Airways of Patients With Stable COPD. *Chest*, **2018**, 153, 851-862	5.3	30
361	The problem of cough and development of novel antitussives. *Pulmonary Pharmacology and Therapeutics*, **2007**, 20, 416-22	3.5	30
360	Posture and theophylline kinetics. *British Journal of Clinical Pharmacology*, **1985**, 19, 707-9	3.8	30
359	Nitric oxide inhibition of basal and neurogenic mucus secretion in ferret trachea in vitro. *British Journal of Pharmacology*, **1996**, 118, 998-1002	8.6	29
358	Corticosteroids: still at the frontline in asthma treatment?. *Clinics in Chest Medicine*, **2012**, 33, 531-41	5.3	28
357	Regulation of Wnt4 in chronic obstructive pulmonary disease. *FASEB Journal*, **2013**, 27, 2367-81	0.9	28
356	Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. *British Journal of Pharmacology*, **2002**, 136, 620-8	8.6	28
355	Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha). *British Journal of Pharmacology*, **2001**, 132, 1261-70	8.6	28
354	Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines. *Respiratory Medicine*, **1996**, 90, 379-84	4.6	28
353	THE CHRONOPHARMACOLOGY AND CHRONOTHERAPY OF ASTHMA **1986**, 229-273		28
352	Protein kinase C isoenzymes in airway smooth muscle. *Biochemical Journal*, **1997**, 324 (Pt 1), 167-75	3.8	27
351	Priming of circulating human eosinophils following late response to allergen challenge. *European Respiratory Journal*, **1996**, 9, 703-8	13.6	27

350	Measurement of 8-isoprostane in exhaled breath condensate. *Methods in Molecular Biology*, **2010**, 594, 73-84	1.4	27
349	A novel approach to partition central and peripheral airway nitric oxide. *Chest*, **2014**, 145, 113-119	5.3	26
348	Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. *Chest*, **2012**, 141, 1233-1242	5.3	26
347	Comparison of the effects of salmeterol and formoterol in patients with severe asthma. *Chest*, **2002**, 121, 1401-6	5.3	26
346	Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action. *Biochemical and Biophysical Research Communications*, **2000**, 273, 811-5	3.4	26
345	Development of new drugs for COPD. *Current Medicinal Chemistry*, **2013**, 20, 1531-40	4.3	26
344	Small airway fibrosis in COPD. *International Journal of Biochemistry and Cell Biology*, **2019**, 116, 105598	5.6	25
343	Defective sirtuin-1 increases IL-4 expression through acetylation of GATA-3 in patients with severe asthma. *Journal of Allergy and Clinical Immunology*, **2016**, 137, 1595-1597.e7	11.5	25
342	Sputum myeloperoxidase in chronic obstructive pulmonary disease. *European Journal of Medical Research*, **2014**, 19, 12	4.8	25
341	Correlation between Eicosanoids in Bronchoalveolar Lavage Fluid and in Exhaled Breath Condensate. *Disease Markers*, **2011**, 30, 213-220	3.2	25
340	Pharmacology of airways and vessels in lung slices in situ: role of endogenous dilator hormones. *Respiratory Research*, **2006**, 7, 111	7.3	25
339	Slower rise of exhaled breath temperature in chronic obstructive pulmonary disease. *European Respiratory Journal*, **2003**, 21, 439-43	13.6	25
338	Transforming growth factor-beta1 inhibits beta2-adrenoceptor gene transcription. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2000**, 362, 520-5	3.4	25
337	Glucocorticoids reduce tachykinin NK2 receptor expression in bovine tracheal smooth muscle. *European Journal of Pharmacology*, **1998**, 344, 99-106	5.3	25
336	beta(2)-adrenoceptor agonist-induced upregulation of tachykinin NK(2) receptor expression and function in airway smooth muscle. *American Journal of Respiratory Cell and Molecular Biology*, **1999**, 21, 409-17	5.7	25
335	Anti-IgE antibody therapy for asthma. *New England Journal of Medicine*, **1999**, 341, 2006-8	59.2	25
334	Nitric oxide and asthma. *Research in Immunology*, **1995**, 146, 698-702		25
333	Molecular mechanisms of antiasthma therapy. *Annals of Medicine*, **1995**, 27, 531-5	1.5	25

332	Lack of effect of zaprinast on methacholine-induced contraction and inositol 1,4,5-trisphosphate accumulation in bovine tracheal smooth muscle. *British Journal of Pharmacology*, **1991**, 103, 1119-25	8.6	25
331	Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. *British Journal of Clinical Pharmacology*, **2015**, 79, 492-500	3.8	24
330	Identifying Molecular Targets for New Drug Development for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. *Seminars in Respiratory and Critical Care Medicine*, **2015**, 36, 508-22	3.9	24
329	Inhaled Aerosol Distribution in Human Airways: A Scintigraphy-Guided Study in a 3D Printed Model. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2016**, 29, 525-533	3.8	24
328	Novel drugs for treating asthma. *Current Allergy and Asthma Reports*, **2001**, 1, 164-73	5.6	24
327	Tumour necrosis factor alpha causes retention of activated glucocorticoid receptor within the cytoplasm of A549 cells. *Biochemical and Biophysical Research Communications*, **1996**, 225, 545-50	3.4	24
326	Phenotypic comparison between smoking and non-smoking chronic obstructive pulmonary disease. *Respiratory Research*, **2020**, 21, 50	7.3	23
325	The size of the problem of managing asthma. *Respiratory Medicine*, **2004**, 98 Suppl B, S4-8	4.6	23
324	Dexamethasone inhibits ozone-induced gene expression of macrophage inflammatory protein-2 in rat lung. *FEBS Letters*, **1995**, 363, 285-8	3.8	23
323	Platelet-activating factor-induced enhancement of superoxide anion generation in guinea-pigs. *European Journal of Pharmacology*, **1993**, 232, 7-12	5.3	23
322	Effects of aerosolised substance P on lung resistance in guinea-pigs: a comparison between inhibition of neutral endopeptidase and angiotensin-converting enzyme. *British Journal of Pharmacology*, **1990**, 100, 69-72	8.6	23
321	Airway smooth muscle and disease workshop: phosphoinositide turnover. *The American Review of Respiratory Disease*, **1987**, 136, S17-20		23
320	Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD. *FASEB Journal*, **2016**, 30, 2014-26	0.9	23
319	Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory Cell and Molecular Biology*, **2019**, 60, 445-453	5.7	23
318	Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD. *Frontiers in Pharmacology*, **2018**, 9, 258	5.6	22
317	Optimized dialysis and protease inhibition of sputum dithiothreitol supernatants. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 132-41	10.2	22
316	A system for the production and delivery of monodisperse salbutamol aerosols to the lungs. *International Journal of Pharmaceutics*, **2003**, 254, 243-53	6.5	22
315	Adenosine 5'-monophosphate increases levels of leukotrienes in breath condensate in asthma. *Respiratory Medicine*, **2004**, 98, 651-5	4.6	22

314	High affinity [3H]formoterol binding sites in lung: characterization and autoradiographic mapping. *European Journal of Pharmacology*, **1994**, 269, 35-41		22
313	Purinoceptors in the pulmonary circulation of the rat and their role in hypoxic vasoconstriction. *British Journal of Pharmacology*, **1989**, 98, 367-72	8.6	22
312	Looking for Airways Periostin in Severe Asthma: Could It Be Useful for Clustering Type 2 Endotype?. *Chest*, **2018**, 154, 1083-1090	5.3	22
311	Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 1180-1186	11.5	21
310	Sarcoidosis: Role of non-tuberculosis mycobacteria and Mycobacterium tuberculosis. *International Journal of Mycobacteriology*, **2014**, 3, 225-9	0.9	21
309	Medicine. Neutrophils find smoke attractive. *Science*, **2010**, 330, 40-1	33.3	21
308	Current and Future Therapies for Airway Mucus Hypersecretion. *Novartis Foundation Symposium*, **2008**, 237-253		21
307	Cytokine modulators for allergic diseases. *Current Opinion in Allergy and Clinical Immunology*, **2001**, 1, 555-60	3.3	21
306	Epigenetics and chromatin remodeling play a role in lung disease. *Tanaffos*, **2011**, 10, 7-16	0.5	21
305	Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. *Lancet Respiratory Medicine,the*, **2021**, 9, 149-158	35.1	21
304	A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 1378-1387.e5	5.4	20
303	Senotherapy: A New Horizon for COPD Therapy. *Chest*, **2020**, 158, 562-570	5.3	20
302	A role for M(2) and M(3) muscarinic receptors in the contraction of rat and human small airways. *European Journal of Pharmacology*, **2013**, 702, 109-15	5.3	20
301	Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. *BMJ, The*, **2007**, 335, 513	5.9	20
300	Involvement of inflammatory mediators in the airway responses to trimellitic anhydride in sensitized guinea-pigs. *British Journal of Pharmacology*, **1992**, 106, 828-32	8.6	20
299	Ezrin, a Membrane Cytoskeleton Cross-Linker Protein, as a Marker of Epithelial Damage in Asthma. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 496-507	10.2	20
298	Quercetin restores corticosteroid sensitivity in cells from patients with chronic obstructive pulmonary disease. *Experimental Lung Research*, **2017**, 43, 417-425	2.3	19
297	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. *Trials*, **2015**, 16, 267	2.8	19

296	Effect of 8-iso-prostaglandin F(2 alpha) on acetylcholine release from parasympathetic nerves in guinea pig airways. *European Journal of Pharmacology*, **2001**, 416, 231-4	5.3	19
295	GM-CSF expression in pulmonary epithelial cells is regulated negatively by posttranscriptional mechanisms. *Biochemical and Biophysical Research Communications*, **2001**, 287, 249-53	3.4	19
294	Our changing understanding of asthma. *Respiratory Medicine*, **1989**, 83 Suppl A, 17-22; discussion 22-3	4.6	19
293	The evolving algorithm of biological selection in severe asthma. *Allergy: European Journal of Allergy and Clinical Immunology*, **2020**, 75, 1555-1563	9.3	18
292	Glycogen synthase kinase-3β modulation of glucocorticoid responsiveness in COPD. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2015**, 309, L1112-23	5.8	18
291	Expression of nonmuscle cofilin-1 and steroid responsiveness in severe asthma. *Journal of Allergy and Clinical Immunology*, **2006**, 118, 1090-6	11.5	18
290	Novel therapy for asthma. *Expert Opinion on Investigational Drugs*, **2000**, 9, 25-42	5.9	18
289	Involvement of hydroxyl radicals in neurogenic airway plasma exudation and bronchoconstriction in guinea-pigs in vivo. *British Journal of Pharmacology*, **1996**, 117, 449-454	8.6	18
288	Attenuation of tachykinin-induced airflow obstruction and microvascular leakage in immature airways. *British Journal of Pharmacology*, **1993**, 108, 23-9	8.6	18
287	Cholecystokinin-octapeptide constricts guinea-pig and human airways. *British Journal of Pharmacology*, **1989**, 97, 675-82	8.6	18
286	Neural control of airway function: new perspectives. *Molecular Aspects of Medicine*, **1990**, 11, 351-423	16.7	18
285	The burden of exacerbations in mild asthma: a systematic review. *ERJ Open Research*, **2020**, 6,	3.5	18
284	Pulmonary Diseases and Ageing. *Sub-Cellular Biochemistry*, **2019**, 91, 45-74	5.5	17
283	Pre-clinical Pharmacokinetic and Metabolomic Analyses of Isorhapontigenin, a Dietary Resveratrol Derivative. *Frontiers in Pharmacology*, **2018**, 9, 753	5.6	17
282	Activation of NF-kappaB transcription factor in asthma death. *Histopathology*, **2009**, 54, 507-9	7.3	17
281	Inflammatory response to sputum induction measured by exhaled markers. *Respiration*, **2005**, 72, 594-9	3.7	17
280	Effect of maturation on histamine-induced airflow obstruction and airway microvascular leakage in guinea pig airways. *European Journal of Pharmacology*, **1992**, 215, 51-6	5.3	17
279	Validation of the Exhaled Breath Temperature Measure: Reference Values in Healthy Subjects. *Chest*, **2017**, 151, 855-860	5.3	16

278	The effect of body weight on distal airway function and airway inflammation. *Obesity Research and Clinical Practice*, **2016**, 10, 564-573	5.4	16
277	New drugs for asthma. *Seminars in Respiratory and Critical Care Medicine*, **2012**, 33, 685-94	3.9	16
276	Anti-leukotrienes: here to stay?. *Current Opinion in Pharmacology*, **2003**, 3, 257-63	5.1	16
275	Neuropeptides and airway smooth muscle **1988**, 36, 119-29		16
274	Activation of transcription factor Nrf2 signalling by the sphingosine kinase inhibitor SKI-II is mediated by the formation of Keap1 dimers. *PLoS ONE*, **2014**, 9, e88168	3.7	16
273	Mitochondrial dysfunction in lung ageing and disease. *European Respiratory Review*, **2020**, 29,	9.8	16
272	Pathogenesis of COPD and Asthma. *Handbook of Experimental Pharmacology*, **2017**, 237, 1-21	3.2	15
271	Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide levels in patients with COPD. *European Respiratory Journal*, **2014**, 43, 1504-6	13.6	15
270	Reduced HDAC2 in skeletal muscle of COPD patients. *Respiratory Research*, **2017**, 18, 99	7.3	15
269	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. *BMC Pulmonary Medicine*, **2014**, 14, 166	3.5	15
268	Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary disease. *FASEB Journal*, **2010**, 24, 1192-204	0.9	15
267	Similarities and differences in inflammatory mechanisms of asthma and COPD. *Breathe*, **2011**, 7, 229-238	1.8	15
266	Effect of 5-HT1A receptor agonist, 8-OH-DPAT, on cough responses in the conscious guinea pig. *European Journal of Pharmacology*, **1997**, 332, 201-7	5.3	15
265	5-Azacytidine suppresses RNA polymerase II recruitment to the SLPI gene. *Biochemical and Biophysical Research Communications*, **2005**, 331, 93-9	3.4	15
264	Evidence for post-transcriptional regulation of interleukin-5 by dexamethasone. *Immunology*, **2003**, 109, 527-35	7.8	15
263	Clinical outcome of adding long-acting beta-agonists to inhaled corticosteroids. *Respiratory Medicine*, **2001**, 95 Suppl B, S12-6	4.6	15
262	Prostaglandins mediate bradykinin-induced reduction of exhaled nitric oxide in asthma. *European Respiratory Journal*, **1999**, 14, 1023-7	13.6	15
261	Inhibition of excitatory non-adrenergic non-cholinergic bronchoconstriction in guinea-pig airways in vitro by activation of an atypical 5-HT receptor. *British Journal of Pharmacology*, **1994**, 111, 1095-102	8.6	15

260	Pharmacological modulation of inhaled sodium metabisulphite-induced airway microvascular leakage and bronchoconstriction in the guinea-pig. *British Journal of Pharmacology*, **1992**, 107, 481-7	8.6	15
259	Glottal Aperture and Buccal Airflow Leaks Critically Affect Forced Oscillometry Measurements. *Chest*, **2015**, 148, 731-738	5.3	14
258	Smoking cessation in COPD causes a transient improvement in spirometry and decreases micronodules on high-resolution CT imaging. *Chest*, **2014**, 145, 1006-1015	5.3	14
257	Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. *Allergy and Asthma Proceedings*, **2012**, 33, 140-4	2.6	14
256	What is the role of nerves in chronic asthma and symptoms?. *American Journal of Respiratory and Critical Care Medicine*, **1996**, 153, S5-8	10.2	14
255	Normal bronchial blood flow in COPD is unaffected by inhaled corticosteroids and correlates with exhaled nitric oxide. *Chest*, **2007**, 131, 1075-81	5.3	14
254	Molecular basis for corticosteroid action in asthma. *Chemical Immunology and Allergy*, **2000**, 78, 72-80		14
253	Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation. *Biochemical Society Transactions*, **1996**, 24, 267S	5.1	14
252	Simvastatin up-regulates adenosine deaminase and suppresses osteopontin expression in COPD patients through an IL-13-dependent mechanism. *Respiratory Research*, **2016**, 17, 104	7.3	14
251	Novel therapy for COPD. *Expert Opinion on Investigational Drugs*, **2000**, 9, 3-23	5.9	13
250	Exhaled nitric oxide. *Current Opinion in Anaesthesiology*, **1996**, 9, 542-548	2.9	13
249	Effect of an inhaled histamine H3-receptor agonist on airway responses to sodium metabisulphite in asthma. *British Journal of Clinical Pharmacology*, **1993**, 35, 55-7	3.8	13
248	Effect of formoterol, a long-lasting beta 2-adrenoceptor agonist, against methacholine-induced bronchoconstriction. *British Journal of Clinical Pharmacology*, **1990**, 29, 321-4	3.8	13
247	Decreased percentage of CD4(+)Foxp3(+)TGF-β(+) and increased percentage of CD4(+)IL-17(+) cells in bronchoalveolar lavage of asthmatics. *Journal of Inflammation*, **2014**, 11, 22	6.7	12
246	A single inhaler for asthma?. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 171, 95-6	10.2	12
245	Future drug therapy for asthma. *Clinical and Experimental Allergy*, **1991**, 21 Suppl 1, 80-5	4.1	12
244	Autoradiographic localization of leukotriene C4 and D4 binding sites in guinea-pig lung. *Prostaglandins*, **1988**, 35, 503-13		12
243	Bacterial load and defective monocyte-derived macrophage bacterial phagocytosis in biomass smoke-related COPD. *European Respiratory Journal*, **2019**, 53,	13.6	12

242	Comparison of Symbicort® versus Pulmicort® on steroid pharmacodynamic markers in asthma patients. *Respiratory Medicine*, **2011**, 105, 1784-9	4.6	11
241	Calcium, calcium channel blockade and airways function. *Acta Pharmacologica Et Toxicologica*, **1986**, 58 Suppl 2, 91-111		11
240	Circulating autoantibodies to recombinant lipocortin-1 in asthma. *Respiratory Medicine*, **1991**, 85, 121-4	4.6	11
239	Chemokine receptor CXCR2 antagonism to prevent airways inflammation. *Drugs of the Future*, **2011**, 36, 465	2.3	11
238	Overcoming steroid insensitivity in smoking asthmatics. *Current Opinion in Investigational Drugs*, **2008**, 9, 470-7		11
237	Osteoprotegerin in sputum is a potential biomarker in COPD. *Chest*, **2011**, 140, 76-83	5.3	10
236	Effect of nitric oxide synthesis inhibition with nebulized L-NAME on ventilation-perfusion distributions in bronchial asthma. *European Respiratory Journal*, **1998**, 12, 865-71	13.6	10
235	Differential effects of phosphoramidon on neurokinin A- and substance P-induced airflow obstruction and airway microvascular leakage in guinea-pig. *British Journal of Pharmacology*, **1991**, 104, 945-9	8.6	10
234	Asthma mechanisms. *Medicine*, **2016**, 44, 265-270	0.6	10
233	Impaired Dual-Specificity Protein Phosphatase DUSP4 Reduces Corticosteroid Sensitivity. *Molecular Pharmacology*, **2017**, 91, 475-481	4.3	9
232	The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. *Journal of Allergy and Clinical Immunology*, **2015**, 136, 501-2.e6	11.5	9
231	Coordinated regulation of IL-4 and IL-13 expression in human T cells: 3C analysis for DNA looping. *Biochemical and Biophysical Research Communications*, **2012**, 417, 996-1001	3.4	9
230	Potential Novel Therapies for Chronic Obstructive Pulmonary Disease. *Novartis Foundation Symposium*, **2008**, 255-272		9
229	Emerging targets for COPD therapy. *Inflammation and Allergy: Drug Targets*, **2005**, 4, 675-83		9
228	Pathophysiology of Asthma **2002**, 343-359		9
227	New treatments for asthma. *European Journal of Internal Medicine*, **2000**, 11, 9-20	3.9	9
226	Sputum induction as a method of analyzing pulmonary cells: reproducibility and acceptability. *Journal of Asthma*, **1999**, 36, 335-41	1.9	9
225	Role of Endothelium in the Control of Pulmonary Vascular Tone. *Endothelium: Journal of Endothelial Cell Research*, **1994**, 2, 11-33		9

224	Oxidative stress induces NF kappa B DNA binding and inducible NOS mRNA in the human epithelial cell line A549. *Biochemical Society Transactions*, **1994**, 22, 186S	5.1	9
223	Effect of inhaled platelet-activating factor on circulating neutrophils and platelets in vivo and ex vivo in man. *Prostaglandins*, **1988**, 36, 343-54		9
222	Telomere Shortening in Alveolar Macrophages of Smokers and COPD Patients~!2010-02-18~!2010-03-05~!2010-04-15~!. *The Open Pathology Journal*, **2010**, 4, 23-29		9
221	Oscillating Positive Expiratory Pressure on Respiratory Resistance in Chronic Obstructive Pulmonary Disease With a Small Amount of Secretion: A Randomized Clinical Trial. *Medicine (United States)*, **2015**, 94, e1845	1.8	8
220	ABC of chronic obstructive pulmonary disease. Future treatments. *BMJ, The*, **2006**, 333, 246-8	5.9	8
219	Isoprostanes and asthma. *Drug Discovery Today: Therapeutic Strategies*, **2006**, 3, 287-292		8
218	Asthma guidelines: recommendations versus reality. *Respiratory Medicine*, **2004**, 98 Suppl A, S1-7	4.6	8
217	Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis.. *European Respiratory Journal*, **2022**,	13.6	8
216	Evaluation of Individuals at Risk for COPD: Beyond the Scope of the Global Initiative for Chronic Obstructive Lung Disease. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)*, **2016**, 3, 653-667	2.7	8
215	Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model. *Journal of Immunology*, **2020**, 205, 2489-2498	5.3	8
214	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 3069-3077.e6	5.4	8
213	Effects of an Airway Clearance Device on Inflammation, Bacteriology, and Mucus Transport in Bronchiectasis. *Respiratory Care*, **2017**, 62, 1067-1074	2.1	7
212	Drugs for airway disease. *Medicine*, **2008**, 36, 181-190	0.6	7
211	Effect of cigarette smoking on haem-oxygenase expression in alveolar macrophages. *Respiratory Medicine*, **2004**, 98, 530-5	4.6	7
210	Effect of frusemide on the induction and potentiation of cough induced by prostaglandin F2 alpha. *British Journal of Clinical Pharmacology*, **1992**, 33, 514-6	3.8	7
209	Effect of nedocromil sodium on down-regulation of pulmonary beta-adrenoceptors. *Clinical Science* , **1989**, 76, 599-602	6.5	7
208	Autoradiographic mapping of beta-adrenoceptors in human skin **1996**, 288, 549		7
207	The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial. *European Respiratory Journal*, **2021**, 57,	13.6	7

206	SARS-CoV-2 infects lung epithelial cells and induces senescence and an inflammatory response in patients with severe COVID-19		7
205	Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway. *Respiratory Research*, **2015**, 16, 102	7.3	6
204	Defective antioxidant gene regulation in COPD: a case for broccoli. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 552-4	10.2	6
203	Increased Eosinophil Responsiveness to Platelet-Activating Factor in Asthma. *Clinical Science*, **1988**, 74, 5P-5P		6
202	Modulation of Neurotransmitter Release from Airways Nerves **1994**, 209-259		6
201	New treatments for chronic obstructive pulmonary disease. *Annali DelllIstituto Superiore Di Sanita*, **2003**, 39, 573-82	1.6	6
200	Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation. *European Respiratory Journal*, **2019**, 54,	13.6	5
199	COPD as a disease of accelerated lung aging(a). *Revista Portuguesa De Pneumologia*, **2009**, 15, 743-6		5
198	The mode of action of corticosteroids in asthma. *Research in Immunology*, **1998**, 149, 225-226		5
197	The management of newly identified asthma in primary care in England. *Primary Care Respiratory Journal: Journal of the General Practice Airways Group*, **2002**, 11, 120-122		5
196	The role of inflammation and anti-inflammatory medication in asthma. *Respiratory Medicine*, **2002**, 96, S9-S15	4.6	5
195	Extracellular signal-regulated kinase 1/2 control Ca(2+)-independent force development in histamine-stimulated bovine tracheal smooth muscle. *British Journal of Pharmacology*, **2000**, 131, 981-9	8.6	5
194	Endotoxin and steroid effects of nitric oxide synthase mRNA expression in rat lung and other tissues. *Biochemical Society Transactions*, **1994**, 22, 188S	5.1	5
193	Biochemical and pharmacological interactions between the papaverine derivative, AH 21-132, and methacholine in bovine tracheal smooth muscle. *European Journal of Pharmacology*, **1990**, 183, 2157-2158	5.3	5
192	CIRCULATING CATECHOLAMINES IN ASTHMA. *Clinical Physiology*, **1981**, 1, 89-93		5
191	Zafirlukast (Accolate). *Drugs of Today*, **1998**, 34, 375-88	2.5	5
190	Reduced denitration activity in peripheral lung of chronic obstructive pulmonary disease. *Tanaffos*, **2012**, 11, 23-9	0.5	5
189	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. *Health Technology Assessment*, **2019**, 23, 1-146	4.4	5

188	Neuropeptides as modulators of airway function. *Agents and Actions Supplements*, **1990**, 31, 175-96	0.2	5
187	Repeated lipopolysaccharide exposure causes corticosteroid insensitive airway inflammation via activation of phosphoinositide-3-kinase pathway. *Biochemistry and Biophysics Reports*, **2016**, 7, 367-373	2.2	5
186	Bicaudal D1 impairs autophagosome maturation in chronic obstructive pulmonary disease. *FASEB BioAdvances*, **2019**, 1, 688-705	2.8	5
185	Targeting cellular senescence as a new approach to chronic obstructive pulmonary disease therapy. *Current Opinion in Pharmacology*, **2021**, 56, 68-73	5.1	5
184	Chronic lung diseases: prospects for regeneration and repair. *European Respiratory Review*, **2021**, 30,	9.8	5
183	Low BMI and weight loss aggravate COPD mortality in men, findings from a large prospective cohort: the JACC study. *Scientific Reports*, **2021**, 11, 1531	4.9	5
182	Current and future therapies for airway mucus hypersecretion. *Novartis Foundation Symposium*, **2002**, 248, 237-49; discussion 249-53, 277-82		5
181	Oxidative Stress in Chronic Obstructive Pulmonary Disease. *Antioxidants*, **2022**, 11, 965	7.1	5
180	Protein tyrosine phosphatase PTP-RR regulates corticosteroid sensitivity. *Respiratory Research*, **2016**, 17, 30	7.3	4
179	Chronic obstructive pulmonary disease. *Clinics in Chest Medicine*, **2014**, 35, xiii	5.3	4
178	New drugs and targets for asthma and COPD. *Progress in Respiratory Research*, **2010**, 3-23		4
177	Neurogenic inflammation in the airways. *NeuroImmune Biology*, **2003**, 437-449		4
176	Nuclear factor-kappaB does not mediate the inhibitory effects of dexamethasone on granulocyte-macrophage colony-stimulating factor expression. *Immunology*, **2004**, 111, 430-4	7.8	4
175	Cytokine-directed therapies in asthma. *Allergology International*, **2003**, 52, 53-63	4.4	4
174	Activation of guinea pig eosinophil respiratory burst by leukotriene B4: role of protein kinase C. *Fundamental and Clinical Pharmacology*, **1992**, 6, 353-8	3.1	4
173	Localization of beta pre-protachykinin mRNA in nodose ganglion. *Neuropeptides*, **1991**, 20, 145-50	3.3	4
172	Platelet Activating Factor Increases Vascular Permeability in Guinea Pig Airways. *Clinical Science*, **1986**, 71, 1P-1P		4
171	Glucocorticosteroids **1998**, 725-766		4

170	Positioning As-needed Budesonide-Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. *Annals of the American Thoracic Society*, **2021**, 18, 2007-2017	4.7	4
169	Cigarette smoke-induced impairment of autophagy in macrophages increases galectin-8 and inflammation. *Scientific Reports*, **2021**, 11, 335	4.9	4
168	Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: Association with inflammatory mediators and cells. *Journal of Critical Care*, **2018**, 44, 161-167	4	4
167	A DPOC como uma doen de envelhecimento acelerado. *Revista Portuguesa De Pneumologia*, **2009**, 15, 743-746		3
166	Chronic obstructive pulmonary disease in non-smokers Authors' reply. *Lancet, The*, **2009**, 374, 1965-1966	40	3
165	Neural mechanisms in asthma: new developments. *Pediatric Pulmonology*, **1997**, 16, 82-3	3.5	3
164	Generating monodisperse pharmacological aerosols using the spinning-top aerosol generator. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2006**, 19, 245-53		3
163	Rebuttal by Dr. Barnes. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 974-974	10.2	3
162	The trials and tribulations of anti-IL-5 em leader. *Journal of Allergy and Clinical Immunology*, **2002**, 109, 575-6	11.5	3
161	The Need for New Therapy **2001**, 31, 2-5		3
160	Cytokine mRNA profiles of normal and asthmatic peripheral blood cells and endobronchial biopsies. *Biochemical Society Transactions*, **1996**, 24, 315S	5.1	3
159	Asthma therapy with aerosols: clinical relevance for the next decade. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **1996**, 9, 131-41		3
158	Effects of nedocromil sodium on airway microvascular leakage and neural reflexes. *Drugs*, **1989**, 37 Suppl 1, 94-100; discussion 127-36	12.1	3
157	The role of neurotransmitters in bronchial asthma. *Lung*, **1990**, 168 Suppl, 57-65	2.9	3
156	Autonomic Control of Airway Function in Asthma. *Chest*, **1987**, 91, 45S-48S	5.3	3
155	Comparison of the Cardiovascular and Respiratory Effects of Substance P and Neurokinin A in Man. *Clinical Science*, **1987**, 72, 41P-41P		3
154	Histamine, Substance P and Neurogenic Flare in Human Skin. *Clinical Science*, **1985**, 68, 23P-24P		3
153	New concepts in the pathogenesis of bronchial hyperresponsiveness. *Agents and Actions Supplements*, **1987**, 21, 225-37	0.2	3

152	Transcription Factors **1998**, 459-474		3
151	Managing COPD **2013**,		3
150	Endo-phenotyping of COPD patients. *Expert Review of Respiratory Medicine*, **2021**, 15, 27-37	3.8	3
149	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. *Drug Safety*, **2021**, 44, 467-478	5.1	3
148	David Jack (1924–2011) who revolutionised the treatment of asthma. *Thorax*, **2012**, 67, 266-267	7.3	2
147	Biology and Assessment of Airway Inflammation **2012**, 75-88		2
146	Inflammation in COPD. *Clinical Respiratory Journal*, **2011**, 5, 1-2	1.7	2
145	Why does asthma become persistent?. *American Journal of Respiratory and Critical Care Medicine*, **1996**, 153, S23-5	10.2	2
144	Reduced Acetylation of Histone 4 in Corticosteroid-Resistant and Corticosteroid-Dependent Asthma. *Clinical Science*, **2001**, 100, 12P-12P		2
143	Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD.. *Thorax*, **2022**,	7.3	2
142	Immunological Features of Chronic Obstructive Pulmonary Disease (COPD) Induced by Indoor Pollution and Cigarette Smoke. *Tanaffos*, **2012**, 11, 6-17	0.5	2
141	Exhaled Breath Condensate **2004**, 1-9		2
140	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
139	Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
138	Update on asthma. *Israel Medical Association Journal*, **2003**, 5, 68-72	0.9	2
137	Autophagy in asthma and chronic obstructive pulmonary disease. *Clinical Science*, **2022**, 136, 733-746	6.5	2
136	Updates in Chronic Obstructive Pulmonary Disease for the Year 2014. *Turkish Thoracic Journal*, **2015**, 16, 86-96		1
135	No Evidence That Electric Charge Increases Inhaled Ultrafine Particle Deposition in Human Lungs. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 1301-1303	10.2	1

134	Drugs for airway disease. *Medicine*, **2012**, 40, 228-237	0.6	1
133	What Does the Future Hold for the Therapy of COPD?. *Milestones in Drug Therapy*, **2014**, 129-146		1
132	Autonomic Control of the Lower Airways **2012**, 201-204		1
131	T5 Circulating endothelial progenitor cells in smokers and patients with COPD are dysfunctional due to increased DNA damage and senescence. *Thorax*, **2013**, 68, A2.3-A3	7.3	1
130	C4 Drugs for the treatment of airway disease **2011**, 321-357		1
129	Genomics in the Evaluation and Management of Chronic Obstructive Pulmonary Disease **2010**, 603-615		1
128	Novel mechanisms and new therapies for chronic obstructive pulmonary disease. *Therapy: Open Access in Clinical Medicine*, **2009**, 6, 795-804		1
127	Chronic obstructive pulmonary disease: reasons for optimism. *Therapy: Open Access in Clinical Medicine*, **2009**, 6, 769-770		1
126	Muscarinic receptor subtypes in airways. *Research in Immunology*, **1998**, 149, 201-202		1
125	Future therapies for chronic obstructive pulmonary disease. *Journal of Organ Dysfunction*, **2008**, 4, 66-70		1
124	A blood test for lung fibrosis. *PLoS Medicine*, **2008**, 5, e98	11.6	1
123	Introducing expert review of respiratory medicine. *Expert Review of Respiratory Medicine*, **2007**, 1, 1-2	3.8	1
122	Chemokines in COPD859-866		1
121	Molecular mechanisms of atopy. *Mediators of Inflammation*, **2001**, 10, 285-8	4.3	1
120	Clinical Studies on New Drugs **2001**, 31, 48-51		1
119	From pathophysiological mechanisms to pharmacological treatment of childhood asthma. *Pediatric Pulmonology*, **1995**, 11, 40-1	3.5	1
118	T cell receptor repertoire in peripheral blood and bronchial biopsies from normal and asthmatic subjects. *Biochemical Society Transactions*, **1996**, 24, 316S	5.1	1
117	Barnes and Adcock reply. *Trends in Pharmacological Sciences*, **1994**, 15, 139	13.2	1

116	The low-chloride cough response is not inhibited by a single, high dose of aspirin. *British Journal of Clinical Pharmacology*, **1992**, 34, 370-2	3.8	1
115	Functional Characteristics of Beta-Adrenergic Receptors of the Intact Eosinophil. *Clinical Science*, **1989**, 76, 14P-14P		1
114	Platelet Activating Factor (PAF) Stimulates Phosphoinositide (PI) Metabolism in Guinea Pig Eosinophils. *Clinical Science*, **1989**, 76, 45P-45P		1
113	Dilator Action of Ligustrazine on Human and Rat Pulmonary Arteries. *Clinical Science*, **1989**, 77, 27P-27P		1
112	Preventative therapy in adults with asthma. *Respiratory Medicine*, **1991**, 85, 355-7	4.6	1
111	Influence of Autonomic Blockade on Cardiovascular effects of Infused Adenosine in Man. *Clinical Science*, **1986**, 71, 45P-45P		1
110	Effects of Infused Adenosine on the Cardiovascular Responses to Orthostasis in Man. *Clinical Science*, **1987**, 72, 9P-9P		1
109	Effect of A Platelet Activating Factor (PAF) Antagonist (Web 2086) on Paf Induced Airway Microvascular Leakage and Platelet Aggregation. *Clinical Science*, **1987**, 72, 68P-68P		1
108	Bradykinin-Induced Microvascular Leakage in Guinea Pig Airways: Involvement of Platelet Activating Factor and Prostanoids. *Clinical Science*, **1988**, 74, 29P-29P		1
107	Evidence for Platelet-Activatinc Factor as a Mediator of Hypoxic Pulmonary Vasoconstriction. *Clinical Science*, **1988**, 75, 21P-21P		1
106	Plasma Catecholamine Concentrations in Acute Severe Asthma and Antigen-Induced Bronchoconstriction. *Clinical Science*, **1984**, 67, 34P-35P		1
105	Nifedipine Prolongs Isoprenaline-Induced Bronchodilatation in Normal Subjects. *Clinical Science*, **1984**, 67, 62P-62P		1
104	The Effect of Posture on Slow Release Theophylline Pharmacokinetics. *Clinical Science*, **1985**, 68, 4P-5P		1
103	The Effect of Vasoactive Intestinal Peptide on Human Airway Smooth Muscle in-vitro. *Clinical Science*, **1985**, 68, 58P-58P		1
102	The Influence of Epithelium on Airway Smooth Muscle Contraction. *Clinical Science*, **1985**, 68, 59P-59P		1
101	Role of Endogenous Opiates in Control of Breathing. *Clinical Science*, **1981**, 61, 4P-5P	6.5	1
100	Identification of Novel Therapeutic Targets in COPD. *Tanaffos*, **2011**, 10, 9-14	0.5	1
99	COPD and Asthma: Effects Beyond the Respiratory System. *Tanaffos*, **2012**, 11, 9	0.5	1

98	CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Overview **2006**, 429-439		1
97	Oxidative Stress in COPD. *Oxidative Stress in Applied Basic Research and Clinical Practice*, **2014**, 115-129		1
96	Pathophysiology of Allergic Inflammation **2009**, 455-472		1
95	NANC Nerves and Neuropeptides **1998**, 423-457		1
94	Glucocorticosteroids: current and future directions. *British Journal of Pharmacology*, **2011**, 163, 29-43	8.6	1
93	Glucocorticosteroids715-731		1
92	Drugs for the treatment of asthma and COPD **2005**, 281-344		1
91	Painful subcutaneous nodules in a patch of livedo reticularis. *International Journal of Dermatology*, **2017**, 56, e44-e46	1.7	0
90	P184 Macrophage phagocytosis in COPD patients at exacerbation compared to stable state. *Thorax* , **2013**, 68, A159.1-A159	7.3	0
89	Pathophysiology of Allergic Inflammation **2014**, 327-342		0
88	Case Report: Ketogenic Diet Is Associated With Improvements in Chronic Obstructive Pulmonary Disease. *Frontiers in Medicine*, **2021**, 8, 699427	4.9	0
87	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. *Trials*, **2021**, 22, 213	2.8	0
86	Identification of coronavirus particles by electron microscopy: a complementary tool for deciphering COVID-19.. *European Respiratory Journal*, **2022**,	13.6	0
85	The Application of Analytical Technique Applied to Expired Air as a Means of Monitoring Airway and Lung Function **2020**, 129-147		
84	Giants in Chest Medicine: Leonardo M. Fabbri, MD. *Chest*, **2016**, 149, 619-20	5.3	
83	Giants in chest medicine: Margaret Turner-Warwick, DBE, DM, PhD. *Chest*, **2014**, 146, 545-546	5.3	
82	Anti-Inflammatory Therapeutics in COPD: Past, Present, and Future **2013**, 191-213		
81	Inflammatory Mechanisms in Chronic Obstructive Pulmonary Disease **2017**, 1173-1198		

80	Therapy of Airway Disease **2012**, 387-393	
79	Exhaled Nitric Oxide in Clinical Practice: Recent Advances and New Challenges **2013**, 231-241	
78	S66 Targeting anti-ageing molecule AMPK restores corticosteroid sensitivity in COPD. *Thorax*, **2013**, 68, A36.1-A36	7.3
77	S112 HDAC activity in macrophages in experimental rhinovirus infection in COPD. *Thorax*, **2013**, 68, A58.2-A59	7.3
76	P253 Association of Defective Monocyte-Derived Macrophage Phagocytosis with Clinical Phenotypes in Stable COPD. *Thorax*, **2012**, 67, A175.2-A176	7.3
75	Novel targets and therapies in COPD **2012**, 104-120	
74	Pathophysiology of COPD **2009**, 425-442	
73	Neural and Humoral Control of the Airways **2009**, 381-397	
72	Pathophysiology of Asthma **2009**, 399-423	
71	Anticholinergic Bronchodilators **2009**, 615-626	
70	Mediator Antagonists **2009**, 655-662	
69	Future Therapies **2009**, 737-749	
68	Rescue Treatment in Asthma: Response. *Chest*, **2010**, 137, 240-241	5.3
67	Avancés thérapeutiques pouvant modifier l'évolution clinique de la BPCO. *Revue Des Maladies Respiratoires*, **2008**, 25, 16-20	0
66	Genomic Aspects of Chronic Obstructive Pulmonary Disease **2009**, 1098-1109	
65	New aspects of chronic obstructive pulmonary disease. *Journal of Organ Dysfunction*, **2007**, 3, 240-249	
64	Glucocorticosteroids for Asthma. *NeuroImmune Biology*, **2007**, 359-381	
63	Histamine levels following adenosine monophosphate challenge. *Respiratory Medicine*, **2005**, 99, 516	4.6

62 Beclometasone Dipropionate/Formoterol in an HFA-Propelled Pressurised Metered-Dose Inhaler. *Drugs*, **2006**, 66, 1484-1485 12.1

61 CORTICOSTEROIDS | Therapy **2006**, 576-581

60 BRONCHODILATORS | Theophylline **2006**, 292-296

59 Beyond the Dutch Hypothesis. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 1057-1057 10.2

58 How To Design a Negative Study. *Chest*, **2003**, 123, 656 5.3

57 Interleukin-6, Obstructive Sleep Apnea, and Obesity. *Chest*, **2003**, 124, 1622-1623 5.3

56 Glucocorticosteroids **2003**, 32-55

55 Autonomic Control of Airways **2004**, 130-133

54 Drugs for airway disease. *Medicine*, **2003**, 31, 44-51 0.6

53 What are the Mechanisms of Corticosteroid Resistance in Asthma?241-254

52 Are mast cells still important in asthma?. *Revue Francaise Dlallergologie Et Dlimmunologie Clinique*, **2002**, 42, 20-27

51 Eosinophils and airway hyper-responsiveness. *Lancet, The*, **2001**, 357, 1446 40

50 Montelukast for persistent asthma. *Lancet, The*, **2001**, 358, 1455-1456 40

49 Current Therapy for Asthma **2001**, 31, 6-10

48 Pathophysiology of Asthma **1998**, 487-506

47 Mediator Antagonists **1998**, 767-782

46 Recommendations based on guidelines on the management of mild to moderately severe chronic obstructive pulmonary disease: some practical applications in primary care. *Primary Care Respiratory Journal: Journal of the General Practice Airways Group*, **1998**, 6, 35-39

45 Salmeterol/Fluticasone Propionate Combination. *Drugs*, **1999**, 57, 941-943 12.1

44	Dexamethasone action on c-fos and c-jun mRNA and protein in human lung. *Biochemical Society Transactions*, **1994**, 22, 187S	5.1
43	Use of a Fixed Combination 2-Agonist and Steroid Dry Powder Inhaler in Asthma. *American Journal of Respiratory and Critical Care Medicine*, **1995**, 151, 1053-1057	10.2
42	A Comparison of the Cutaneous Actions of Substance P and Calcitonin Gene Related Peptide in Man. *Clinical Science*, **1986**, 70, 54P-54P	
41	Hypoxia and Catecholamine Secretion in Normal Man. *Clinical Science*, **1984**, 67, 58P-59P	
40	Regional Ventilation Perfusion Ratio and Specific Ventilation in Asthmatics Using Positron Emission Tomography (PET). *Clinical Science*, **1984**, 67, 59P-60P	
39	Inhaled Nifedipine Reverses Histamine-Induced Bronchoconstriction in Man. *Clinical Science*, **1985**, 68, 5P-5P	
38	Distribution of Beta-Adrenoceptor Subtypes in Human Lung. *Clinical Science*, **1985**, 68, 35P-35P	
37	Substance P Enhances the Transient Ventilatory Hypoxic Response in Man. *Clinical Science*, **1985**, 69, 59P-59P	
36	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial.. *International Journal of COPD*, **2022**, 17, 273-282	3
35	Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function". *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 4179-4180	5.4
34	Nitric Oxide in Exhaled Air: Relevance in Inflammatory Lung Disease **2000**, 167-183	
33	The Pathogenesis and Treatment of Asthma as an Inflammatory Disease **2000**, 221-236	
32	Inflammatory Mediators and Neural Mechanisms in Severe Asthma. *Lung Biology in Health and Disease*, **2001**, 67-87	
31	Future Therapies **2002**, 641-656	
30	Neural and Humoral Control **2002**, 323-340	
29	Future Therapies for Asthma. *Lung Biology in Health and Disease*, **2002**, 353-382	
28	Autonomic Control of the Airways **2002**, 432-454	
27	Glucocorticoids and Asthma **2003**, 127-134	

26 New drugs for COPD based on advances in pathophysiology **2004**, 189-226

25 Oxidative Stress in COPD **2004**, 61-74

24 Biology and Assessment of Airway Inflammation **2006**, 65-74

23 -Agonists, Anticholinergics, and Other Nonsteroid Drugs **2008**, 471-482

22 Chronic Obstructive Pulmonary Disease (COPD): Biological Mechanisms1

21 Recent Advances in Asthma Management. *European Respiratory & Pulmonary Diseases*, **2018**, 4, 15 0.4

20 Pharmacology of asthma and COPD **2019**, 344-352

19 Molecular Mechanisms of Anti-Asthma Therapy **1995**, 403-409

18 Transcription Factors in Asthma **1998**, 25-45

17 Future Therapies for Asthma **1998**, 795-819

16 Transcription Factors and Inflammatory Lung Disease **1999**, 41-70

15 New Targets for Future Asthma Therapy **1999**, 361-389

14 Signal Transduction Pathways Involved in Glucocorticoid Actions **2010**, 289-309

13 Pharmacologic Principles **2010**, 159-199

12 Targeting Histone Deacetylases in Chronic Obstructive Pulmonary Disease **2011**, 205-215

11 The Future of COPD **2011**, 75-90

10 Epidemiology, Risk Factors and Pathophysiology **2011**, 7-28

9 Glucocorticoids: Pharmacology and Mechanisms16-37

8 Chronic Obstructive Pulmonary Disease (COPD)245-265

7 The Future of COPD **2013**, 77-92

6 Oxidative Stress in Chronic Obstructive Pulmonary Disease **2014**, 314-348

5 Accelerated Lung Aging and Cellular Senescence in COPD **2022**, 583-593

4 Other Drugs for Asthma and COPD **2022**, 729-740

3 Inflammatory and Immune Mechanisms in COPD **2022**, 549-558

2 Asthmatic patients **2021**, 136-153

1 New Drugs for the Treatment of Allergy and Asthma1712-1739